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Neurodegenerative diseases have been closely linked to dysfunction of 
mitochondria. For example, Leber's hereditary optic neuropathy is associated with 
mutations in mitochondrial complex I. To create an in vivo animal model of 
neurodegeneration for studying the mechanisms and treatments of neurodegenerative 
diseases, the mouse eye was injected with the pesticide rotenone, a specific 
mitochondrial complex I inhibitor. Then, the neurotoxicity of rotenone on the retina 
was characterized at the cellular level. Finally, a therapeutic intervention was tested 
using the model. A dose of methylene blue was found to effectively prevent the 
neurodegeneration caused by rotenone. 
Following intravitreal injection of rotenone, the retinal ganglion cell layer 
(GCL) and the retinal nerve fiber layer (RNFL) showed degeneration as indicated by 
 viii 
the reduction of their thicknesses. The maximum reduction in the GCL and RNFL 
thickness in complex I staining was around 40% and 89% respectively at 24 h. The 
GCL thickness reduction was also verified with cresyl violet staining. The number of 
GCL cells was reduced by 21% (cell profile counts) and 23% (unbiased stereological 
cell counts) in rotenone-treated eyes. There was a preferential reduction in the 
proportion of larger cells, while no overall cellular morphometric changes (soma area, 
perimeter, and diameter) were observed. Therefore, the reduction in GCL thickness 24 
h after rotenone microinjection could be accounted for by cell loss and nerve fiber 
shrinkage, but not by overall soma size change. 
This optic neuropathy model was used to test the hypothesis that methylene 
blue, a reduction–oxidation agent that can act as a powerful antioxidant, may be 
protective against rotenone. Rotenone-induced neurodegeneration in the retinal 
ganglion cell layer 24 h after injection was completely prevented by the injection of 
methylene blue along with rotenone, as indicated by both the GCL thickness and cell 
numbers. 
This is the first animal model of optic neuropathy resulting from mitochondrial 
dysfunction, and our studies suggest that it could be used as a convenient means to test 
new treatments to prevent neurodegeneration. It was concluded that methylene blue 
may be a promising therapeutic agent in optic neuropathy and perhaps other 
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Chapter 1: Introduction 
 
1.1 MITOCHONDRIA AND MITOCHONDRIAL DISEASES 
Mitochondria are cytoplasmic organelles and the site of cellular respiration 
(aerobic metabolism) in almost all eukaryotes (the organisms composed of one or 
more cells containing visibly evident nuclei and organelles). The most important 
function of mitochondria is to convert energy from nutrient molecules (substrates) and 
to store it in the form of adenosine triphosphate (ATP). ATP is the universal energy 
source for performing a wide range of cellular functions. We cannot survive, even for 
a moment, without a sufficient supply of ATP. In order to carry out energy conversion, 
mitochondria reduce oxygen to water using some of the energy provided by substrates. 
The ATP-generating process in which oxygen serves as the ultimate electron acceptor 
in mitochondria is called cellular respiration (Stryer, 1999). The primary purpose of 
our respiratory and circulatory systems is to deliver oxygen to the tissues for use by 
mitochondria, and to eliminate carbon dioxide.  
 
1.1.1 Structure and function of mitochondria 
Each mitochondrion has an outer membrane that is permeable to large 
molecules, and an inner membrane that is relatively impermeable and contains the 
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electron transport enzyme complexes. The inner compartment of the mitochondrion, 
enclosed by the inner membrane, is the matrix where the Krebs cycle takes place 
(Figure 1.1).  
The electron transport complexes are transport enzymes embedded in the inner 
mitochondrial membrane, designated complexes I through V (Figure 1.1). They can 
use molecular oxygen to oxidize both NADH and FADH2, which are the electron 
donors from nutrient molecules that are produced by the Krebs cycle. Complexes I and 
II collect electrons and transfer them to ubiquinone (coenzyme Q10). The electrons 
then move sequentially to complex III, cytochrome c, complex IV, and finally, to 
oxygen, which is the terminal electron acceptor (Figure 1.1). The energy of electron 
transport can then be used by the complexes to pump hydrogen protons into the 
intermembrane space, producing an electrochemical proton gradient that stores 
potential energy. The flow of protons from the intermembrane space back into the 
inner matrix through Complex V (ATP synthase) allows the complex to use the energy 
stored in the proton gradient to condense ADP with inorganic phosphate into ATP, a 
process called oxidative phosphorylation (Voet and Voet, 1995). A very important 
metabolic role of mitochondria is their role in energy metabolism through oxidative 
phosphorylation because the vast majority of cellular ATP is provided by 
mitochondria through oxidative phosphorylation. 
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Figure 1.1: Illustration of mitochondrial complexes and place of action and 
functional organization of oxidative phosphorylation system. Coenzyme 
Q, also called ubiquinone, shuttles electrons from complexes I and II to 
complex III. Complexes I, III, and IV create an electrochemical gradient, 


































1.1.2 Mitochondrial dysfunction is associated with neurodegenerative disorders 
The role of mitochondria in human disease was overlooked until the discovery 
of Luft’s disease (a hypermetablic disorder of striated muscle caused by an abnormal 
quantity and type of mitochondria and characterized by progressive weakness and an 
abnormally increased basal metabolic rate) in 1958 (Luft et al., 1962). Since then, over 
120 human mitochondrial diseases have been discovered in which there are functional 
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disturbances and structural alterations in the mitochondria (Luft, 1994). Most of these 
diseases involve highly energy-dependent cells, such as those in the central nervous 
system, retina, or skeletal muscle system. Many of these diseases are associated with 
specific or inherited mitochondrial DNA point mutations and DNA rearrangement 
mutations (deletions and insertions) accompanying electron transport chain 
deficiencies (Beal, 1998; DiMauro, 2001; Wallace et al., 1999). A critical role for 
mitochondrial dysfunction in neurodegenerative diseases is gaining increasing 
acceptance.  
Human mitochondrial DNA (mtDNA) is a 16569 base pair circular and highly 
compact double-stranded DNA. It has only 37 genes, of which 13 encode subunits of 
mitochondrial complexes required for oxidative phosphorylation, two genes encode 
ribosomal RNAs (rRNAs), and 22 genes encode transfer RNAs (tRNAs) required for 
their translation (DiMauro, 2001). Of the 13 subunits encoded by mtDNA, seven 
subunits belong to complex I, one to complex III, three to complex IV, and two to 
ATP synthase (Genova et al., 2004). 
The integrity of mtDNA is required for normal mitochondrial function. Many 
types of mutations and deletions in mtDNA have been reported to cause diseases due 
to the dysfunction of mitochondria (DiMauro, 2001). The decline of mitochondrial 
respiratory function is also observed in idiopathic neurodegenerative diseases. 
Mitochondrial dysfunction has widely been accepted to be a major event that 
contributes to the degeneration process in neurodegenerative diseases (Beal, 1998; 
Brown and Wallace, 1994; Valla et al., 2001).  
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Some of the neurodegenerative diseases, their corresponding deficient 
mitochondrial electron transport chain enzymes, and the correspondent common 
enzyme inhibitors (of natural or synthetic origin) are listed in Table 1.1. 
 
Table 1.1: Mitochondrial complex deficiencies, their associated neurodegenerative 
diseases, and common inhibitors corresponding to the complexes. 
Abbreviations: HD - Huntington’s disease (complex II/III deficiency); 
FA - Friedreich’s ataxia (complex I – III deficiency); PD - Parkinson’s 
disease (complex I deficiency), and AD - Alzheimer’s disease (complex 
IV deficiency); ALS - Amyotrophic lateral sclerosis. 
 
Deficient enzymes Diseases Enzyme Inhibitors 
Complex I (NADH-






ALS (Luft, 1994) 
• Rotenone (Degli Esposti, 
1998) 
• MPP+, the active metabolite 
of MPTP and a selective 
inhibitor (Storey et al., 1992) 
• Amytal (Ernster et al., 1963; 
Storey, 1980) 
Complex II (succinate 
dehydrogenase). 
HD; FA (Beal, 
1998) 
• Malonate, reversible inhibitor 
(Beal et al., 1993b) 
• 3-nitropropionic acid (3-NP), 






HD; FA (Beal, 
1998) 
• Antimycin (Bailey et al., 
1999) 
Complex IV (cytochrome 
c oxidase) 
AD (Valla et al., 
2001) 





A dysfunctional mitochondrial electron transport chain decreases ATP 
production and accelerates the generation of free radicals. Radicals are species 
containing one or more unpaired electrons, such as nitric oxide. Free radicals are an 
unavoidable byproduct of cellular respiration, because some electrons can leak away 
from the main path, especially as they pass through ubiquinone, and go directly to 
reduce oxygen molecules to the superoxide anion. In fact, up to 4-5% of oxygen in 
mitochondria is not converted to water by the action of complex IV, but is reduced by 
a single electron leaking from the complexes located up stream of the electron transfer 
chain, therefore becoming superoxide radical (Richter, 1992). Excessive free radicals, 
or more particularly, reactive oxygen species (ROS), can directly lead to oxidative 
stress. Oxidative stress refers to the imbalance between the cellular production of ROS 
and the antioxidant mechanisms that remove them. It has the potential to trigger a 
variety of cellular damage, including lipid peroxidation, DNA fragmentation, and 
modification of proteins. Therefore ROS are a major factor in oxidative cell injury. 
The mitochondrial electron transport chain is the major intracellular source of ROS, 
for example, the superoxide anion and hydrogen peroxide (Genova et al., 2004). 
The central nervous system, including the retina, and the skeletal muscle 
system are particularly vulnerable to oxidative stress because they have (1) very high 
energy and oxygen demands, (2) a limited capacity to use substrates other than 
glucose for ATP synthesis, (3) abundant lipid content, and (4) relatively lower 
antioxidant levels compared to other organs. Neurons, in particular, are extremely 
dependent on mitochondria; they derive more than 90% of their ATP from 
mitochondrial respiration. The human brain comprises only about 2% of human body 
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weight but it accounts for about 20% of the body’s total energy consumption (Raichle 
and Gusnard, 2002; Shulman et al., 2003). About 40% of all oxygen consumption in 
the brain is used to maintain the sodium-potassium gradient across the cell membrane. 
The energy reserves of the CNS are small, and irreversible cellular damage occurs 
after a brief deprivation of either glucose or oxygen, which may trigger a cascade of 
further damage, eventually leading to neuronal cell death, namely neurodegeneration. 
Thus, these tissues have special vulnerability to mitochondrial dysfunction. Oxidative 
stress, the cytotoxic consequences of ROS generation as byproducts of normal 
oxidative metabolism in mitochondria, has been implicated in mitochondrial 
neurodegenerative diseases (Coyle and Puttfarcken, 1993).  
 
1.2 THE RETINA: A MODEL SYSTEM FOR STUDYING THE CENTRAL NERVOUS 
SYSTEM 
The eye (see Figure 1.2 and 1.3) is a fluid-filled sphere enclosed by three 
layers of tissue (Bear et al., 2005). The outmost layer is composed of two types of 
tissue: a tough opaque white fibrous tissue called the sclera, and the cornea, a 
specialized transparent tissue that allows light to enter the eye. The middle layer 
includes three different but continuous structures: the iris, the ciliary body, and the 
choroid. The iris is the colored portion of the eye that can be seen through the cornea 
with the opening in its center, called the pupil. The size of the pupil can be adjusted 
under neural control with the apposing actions of the two sets of muscles in the iris. 
The ciliary body is a ring of tissue that encircles the lens. It includes a muscular 
component that is important for adjusting the refractive power of the lens, and a 
vascular component (the so-called ciliary processes) that produces the fluid to fill the 
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front of the eye. The choroid is composed of a rich capillary bed that serves as the 
main source of blood supply for the photoreceptors of the retina. The innermost layer 
of the eye is the retina, which will be discussed in more detail later on. 





Figure 1.3: A) Cross-section of mouse eye, Nissl stained, 20 µm. B) Cross-section of 





The space between the cornea and the front of the lens is filled with aqueous 
humor, which is a clear, watery liquid that supplies nutrients to the structures with 
which it makes contact. The aqueous humor is produced by the ciliary processes in the 
posterior chamber (the region between the lens and the iris) and flows into the anterior 
chamber through the pupil. A specialized meshwork of cells that lies at the junction of 
the iris and the cornea is responsible for its uptake. Under normal conditions, the rates 
of aqueous humor production and uptake are in equilibrium, maintaining a constant 
intraocular pressure. Abnormally high levels of intraocular pressure, which occur in 
glaucoma, can reduce the blood supply to the eye and eventually damage retinal 
neurons. 
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The space between the back of the lens and the surface of the retina is filled 
with a thick, gelatinous substance called the vitreous humor, which accounts for about 
80% of the volume of the eye in humans. In addition to maintaining the shape of the 
eye, the vitreous humor contains phagocytic cells that remove blood and other debris 
that might otherwise interfere with light transmission. However, the housekeeping 
abilities of the vitreous humor are limited, as seen in many middle-aged and elderly 
individuals with vitreal “floaters”. Floaters are collections of debris that are too large 
for phagocytic consumption; they remain in the vitreous humor and cast annoying 
shadows on the retina. 
Consistent with its status as a part of the central nervous system, the retina is 
the only structure in the eye that contains neurons connected to photoreceptors capable 
of converting light into electric signals. These signals are transmitted through the optic 
nerve to other higher centers in the brain for further processing necessary for visual 
perception. Besides photoreceptors, there are four types of neurons in the retina: 
bipolar cells, ganglion cells, horizontal cells, and amacrine cells. The cell bodies and 
processes of these cells are located in five alternating layers within the retina, with the 
cell bodies in the inner nuclear, outer nuclear, and ganglion cell layers, and the 
processes and synaptic contacts in the inner plexiform and outer plexiform layers. A 
two-synapse pathway - photoreceptor cell to bipolar cell to ganglion cell - is the major 
path of information flow from the photoreceptors to the optic nerve. The two other 
types of neurons in the retina, horizontal cells and amacrine cells, are interneurons that 
have their cell bodies in the inner nuclear layer and are primarily responsible for 
lateral interactions within the retina (Reid, 1999).  
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The innermost layer of the retina is the retinal nerve fiber layer (RNFL), 
containing the axons of the ganglion cells. The ganglion cell layer (GCL) contains 
mainly the cell bodies of the ganglion cells and some displaced amacrine cells. The 
inner plexiform layer (IPL) consists of the dendrites of the ganglion cells and the 
neurites (dendrites and axons) of the bipolar cells and the amacrine cells (Figure 1.4). 
The visual information processing of the retina starts when the light hits the 
photoreceptor cells located in the outer surface of the retina, after coming through the 
cornea, the lens, the vitreous body, and the inner layers of the retina including the 
RNFL, GCL, IPL, and INL. However the information flows in the opposite direction 
from the photoreceptors to the ganglion cells, and through their axons to the optic 
nerve, and up to the brain.  
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Figure 1.4: A section of human retina with its corresponding diagram of cells. 






The retina is a well-characterized system that provides unique opportunities to 
investigate a range of neuroscience-related issues in health and disease, from the 
molecular to the systems levels. Its unique features have made it a classic model for 
understanding brain function. The retina has been called an “approachable part of the 
brain” (Dowling, 1987) for the following reasons. 
First of all, despite their peripheral locations, the retina and the optic nerve are 
legitimate parts of the central nervous system. They are derived embryonically from 
the brain region called the “diencephalon”. During development, an outpocketing of 
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the diencephalon is formed, then undergoes invagination to form the optic cup. The 
inner wall of the optic cup gives rise to the retina, while the outer wall gives rise to the 
pigment epithelium.  
Second, the retina is a relatively simple but well-organized neural circuit 
system. It is comprised of only a few classes of neurons, but it has the same types of 
functional elements and neurotransmitters found in other parts of the central nervous 
system (Wassle and Boycott, 1991). The circuit of the retina and the optic nerve is 
arranged in a manner that has been less difficult to unravel than the circuits in other 
areas of the brain. 
Third, the retina allows easy access. In fact, it is the only part of the central 
nervous system that can be visualized without any invasive administration. 
Last, the small size of the retina has even become an advantage in certain 
histological, ultrastructural, and morphometric studies. For instance, tissue processing 
requires less time, and also a great proportion of the eye can be represented in a 
microscopic field. 
The retina is an ideal model system for studies in neuroscience. Developmental 
studies of the retina and the central visual pathways have had a substantial impact on 
other fields of neuroscience, and exploration of retinal circuitry has led to a 





1.3 LEBER’S HEREDITARY OPTIC NEUROPATHY IS LINKED TO MITOCHONDRIAL 
COMPLEX I DYSFUNCTION 
1.3.1 Leber’s hereditary optic neuropathy (LHON) 
LHON, a model disease for mitochondrial neurodegenerative diseases (Brown 
et al., 1992), was first described by Theodor Leber in 1871. It is an inherited form of 
bilateral optic atrophy. It classically manifests as acute or subacute onset with bilateral 
central vision loss associated with the degeneration of the retinal ganglion cell layer 
and the optic nerve. The initial symptom typically is a blurring of vision bilaterally. 
Over weeks or months, the blindspots are progressively enlarged to an absolute central 
scotoma which is a blind or dark spot in the visual field. Typically, the onset and 
progression of blindness is relatively rapid, with both eyes developing vision loss 
within a year. Although the onset age ranges from 10 to 70 or so, the mean age of 
onset is in the mid-20’s for both genders. LHON is one of the neurodegenerative 
diseases (degeneration of the retinal ganglion cells) that are caused by dysfunction of 
mitochondria, especially complex I of the electron transport chain of the mitochondria. 
LHON is the most common cause of blindness in otherwise healthy young men 
(Schapira, 1998).  
It has been agreed broadly that there are three types of mtDNA complex I gene 
mutations that account for the vast majority of LHON cases (Howell, 1998). About 
90-95% of LHON cases are the result of one of the three mtDNA point mutations at 
nucleotide positions 3460/ND1, 11778/ND4 and 14484/ND6, all of which affect 
complex I (Besch et al., 1999; Brown et al., 1992; Beal, 1998). These three mutations 
are called “primary mutations” in the sense that no additional mtDNA mutations are 
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required to cause the disease, and they are not seen in controls. The 11778 mutation in 
ND4 is found in 50% of LHON families (Schapira, 1998). Sixteen other mutations 
associated with LHON are “secondary mutations” because either the mutations must 
occur in some combination or they can be found in controls. 
The peripapillary microangiopathy feature of LHON is tortuous vessels in the 
central retina (Beal et al., 1997). However, in some LHON cases, other more severe 
neurological abnormalities are also observed, the most common of which is early-
onset dystonia associated with basal ganglia degeneration (Wallace et al., 1999). 
Electrophysiological studies of LHON patients have shown desynchronized visual 
evoked potentials (VEPs) during the acute phase and extinguished VEPs during the 
atrophic stage, both indicating retinal ganglion cell dysfunction. However, the patients 
have normal electroretinograms (ERG) and electrooculograms (EOG), which indicate 
the functional integrity of photoreceptors, bipolar cells, and retinal pigment epithelium 
(Sherman and Kleiner, 1994). 
Maternal inheritance shows in some of the LHON families, which led to an 
intensive mtDNA analysis on this disorder, since one unique property of mtDNA is 
that it is passed exclusively through the mother. The few sperm mitochondrial DNA 
copies that may enter the ovum have little effect on the genotype since it is a very 
small portion of several hundreds to thousands of mitochondrial DNA copies 
(Gyllensten et al., 1991). 
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1.3.2 Mitochondrial complex I  
Mitochondrial complex I is also called nicotinamide adenine dinucleotide 
(NADH)-quinone oxidoreductase, NADH-cytochrome c reductase, or NADH 
dehydrogenase. Complex I is the first and the largest complex of the mitochondrial 
respiratory chain. It catalyzes the following reaction: NADH + CoQ + H+  NAD+ + 
CoQH2, transferring electrons from NADH to co-enzyme Q and beginning the 
electron transport chain (ETC). It is a multienzyme, integral membrane protein 
complex of 43 distinct proteins encoded by both nuclear and mitochondrial genomes 
(Greenamyre et al., 2001; Hatefi, 1985). The mtDNA-encoded subunits are all part of 
the membrane arm which is associated with the inner mitochondrial membrane; the 
other arm of this elbow-shaped complex faces the matrix. There are 13 mtDNA-
encoded subunits in mitochondrial complexes, and more than half of them are the 
subunits of complex I (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6). Among these 
subunits, the ND1 subunit is the binding site for quinone, the electron acceptor of 
complex I in the electron transport chain, and rotenone, a specific exogenous complex 
I inhibitor (Hatefi, 1985; Schapira, 1998; Genova et al., 2004).  
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1.4 ROTENONE – A COMPLEX I INHIBITOR 
There is a compelling need for animal models of neurodegenerative diseases. 
LHON attracted our attention because it stimulates the idea of creating an in vivo 
neurodegeneration model using the retina and the optic nerve, the “approachable part 
of the brain” (Dowling, 1987), by impairing the function of mitochondrial complex I. 
Therefore, the first objective of this dissertation was to model mitochondrial toxicity 
using defective complex I. This model has the potential to be used as a means of 
exploring the in vivo mechanism of neuronal cell death as well as treatment, not only 
for LHON or other optic neuropathies, but, more importantly, for neurodegenerative 
diseases in general.  
There are over sixty different types of complex I inhibitors (Degli Esposti, 
1998). They can be classified into two general categories: compounds of natural or of 
commercial origin. However, only a few of them are commonly used.  
Since the reports in early 1960s (e.g. Lindahl and Oberg, 1961) , rotenone has 
become the classic inhibitor of complex I. Over the past few years, it has been widely 
used in studies involving neurodegeneration, especially in Parkinson’s disease (PD) 
(Betarbet et al., 2000; Ferrante et al., 1997), because the brains of PD patients showed 
decreased activity of complex I. Rotenone is the most potent and most abundant 
member of a family called rotenoids, which are of natural origin and are organic 
chemical compounds extracted from the roots of certain species of the bean family 
genera Lonchocarpus and Derris, and often referred to as Cube Root. It is widely used 
as a fish poison in management of fish populations, for example, to remove some or 
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all of the fish from a pond as part of a renovation plan. It is also widely used by 
gardeners because it is especially effective for eliminating the most troublesome of 
pests, such as leaf-eating caterpillars, beetles, and squash bugs. Rotenone is a potent 
and specific inhibitor of mitochondrial complex I, binding to subunit ND1 of complex 
I firmly and irreversibly (Ernster et al., 1963; Singer and Ramsay, 1994). 
 












Other classic complex I inhibitors include 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and amytal, which are both synthetic inhibitors of complex 
I. MPTP can cross the blood–brain barrier because it is lipophilic. It is oxidized to its 
neurotoxic form, 1-methyl-4-phenylpyridinium ion (MPP+) by monoamine oxidase B 
in glial cells (Singer and Ramsay, 1990). MPP+ is selectively accumulated in the 
mitochondrial matrix of dopaminergic neurons by the dopamine re-uptake system 
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(Javitch et al., 1985) due to its positive charge. MPP+ was reported to cause the 
specific toxicity in dopaminergic neurons resulting in Parkinsonism (Greenamyre et 
al., 2001). MPP+ inhibits complex I in the mitochondrial respiratory chain by binding 
at the same site as rotenone (Ramsay et al., 1991). The inhibition of complex I by 
MPP+ in dopaminergic cells is considered to cause the MPTP-induced Parkinsonism.  
Amytal (5-ethyl-5-isoamylbarbituric acid) was also used as one of the first 
inhibitors of complex I (Ernster et al., 1955). However, its inhibition is neither strong 
nor specific. A high concentration of amytal is required for maximal inhibition, and it 
also inhibits other enzymes, for example, choline oxidation (Storey, 1980). Thus, it is 
not the agent of choice for the current study. 
Rotenone was chosen as a complex I inhibitor for our study due to its specific 
features. It is a sensitive and irreversible inhibitor of mitochondrial complex I and it 
has features not found in two other common complex I inhibitors, MPTP and amytal. 
Unlike MPTP, which is selective for dopaminergic neurons and depends on the 
dopamine transporters to gain access to the neurons, rotenone is extremely lipophilic 
and can easily penetrate biological membranes (Ernster et al., 1963) while the highly 
charged 1-methyl-4-phenylpyridinium ion (MPP+, the main metabolite of MPTP) 
would have much more difficulty to pass through. Rotenone is also more potent than 
MPP+ (Heikkila et al., 1986). Rotenone may be a more appropriate model candidate 
than amytal, as rotenone binds to the electron transfer system firmly and irreversibly 
(Ernster et al., 1963). In addition, a study using rotenone includes environmental 
significance. It is a pesticide of natural origin (derived from plants) and found in a 
variety of commercial garden and animal-care products. It is widely used on home-
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grown fruits and vegetables and also commonly used in fishery management in lakes. 
Because rotenone is a naturally occurring and widely used pesticide, studies with 
rotenone may provide clues to an environmental role of pesticides in 
neurodegenerative diseases. Therefore, rotenone is likely to offer a more widely 
applicable model of environmental toxin exposure than MPTP or amytal. 
 
1.5 METHYLENE BLUE - A THERAPEUTIC INTERVENTION 
The purpose of creating a neurodegeneration model is not only to aid the study 
of the mechanisms of neurodegeneration, but more importantly, to meet the need of 
therapeutic interventions. An early study by Lindahl and Oberg (1961) attracted our 
attention because they demonstrated that exposure of intact and excised gill filaments 
to rotenone induced a decreased oxygen consumption, and addition of methylene blue 
(MB), an oxidation-reduction (redox) dye, reduced the inhibition of oxygen uptake 
caused by rotenone and restored up to 83% of the normal respiration (Lindahl and 
Oberg, 1961). This suggested that MB might be effective in reversing the effects of 
rotenone.  
MB is one of the reducible dyes that are “autoxidizable”. Its characteristic 
redox couple feature (Figure 1.5) allows it to be an electron mediator between 
enzymes and substrates, which has attracted considerable interest. In its oxidized form, 
methylene blue retains its blue color, but becomes colorless in its reduced form, 
leucomethylene blue.  
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MB is not only a redox dye but also an FDA-approved drug that has been used 
in clinical medicine for nearly 100 years. The history of safe MB use in humans for 
many years in various treatments makes it additionally attractive. Its traditional uses in 
histological techniques, diagnosis, as well as in disease treatments are based on its 
tissue-staining properties and its oxidative-reductive capacity. Administered locally or 
systemically, it has been used for the detection of anatomic and pathologic structures 
during surgical operations, for example, to mark the blood vessel by applying to the 
adventitia of blood vessels during coronary artery bypass and other vascular 
procedures (Barber et al., 1995); to identify a fistula (a tiny channel or tract that 
develops in the presence of inflammation and infection) and ruptured amniotic 
membranes, or diseased pelvic peritoneum in obstetrics (Manhes et al., 2004); to 
detect glandular tissues, such as on parathyroid glands or pancreatic (Derom et al., 
1993); and to inactivate viruses in fresh frozen plasma and blood products (Floyd et 
al., 2004; Wieding et al., 1993). Therapeutically, methylene blue has long been 
recognized as an effective antidote when administrated systemically in low doses in 
man and in domestic animals due to its reducing action for drug-induced, and some 
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forms of idiopathic, methemoglobinemia (Bodansky and Gutmann, 1947; Clifton and 
Leikin, 2003; Bradberry, 2003; Etteldorf, 1951), and for drug-related encephalopathy 
in cancer chemotherapy with ifosfamide (Kupfer et al., 1994; Kupfer et al., 1996). In 
addition, MB has also been used to treat dementia and manic-depressive psychosis 
(Naylor et al., 1986; Wainwright and Crossley, 2002). 
MB is a suitable treatment candidate for neurodegenerative diseases caused by 
mitochondrial dysfunction because it can enter the nervous tissue as well as its 
mitochondria (Peter et al., 2000; Hassan and Fridovich, 1979; O'Leary et al., 2005; 
Richardson, 2005). O’Leary et al. (2005) have shown that MB was able to cross the 
blood-brain barrier when administered intraperitoneally to rats. The stained brain 
tissue was visible after dissection when deoxidized because MB regained its blue 
color. Pharmacokinetics studies have shown that intravenous administration resulted 
in higher concentration of MB in both blood and brain than oral administration did, 
while MB concentration is much higher in the brain than in the blood after 1 hr 
following intraperitoneal administration (Peter et al., 2000). Hassan and Fridovich 
(1979) have demonstrated that MB is capable of entering the mitochondria and 
diverting a portion of the electron flow to molecular oxygen. Behaviorally, it has been 
shown that methylene blue improved memory retention in inhibitory avoidance 
responses when given immediately after training in rats (Martinez et al., 1978). 
Studies in our laboratory have also found MB enhances spatial memory retention 
impaired by sodium azide (an inhibitor for mitochondrial complex IV) (Callaway et 
al., 2002) or in normal rats (Callaway et al., 2004). 
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Two major pharmacological mechanisms for MB’s protective metabolic 
function have been documented. One mechanism involves improving oxygen 
consumption. MB acts as a redox agent that increases mitochondrial respiration by 
shuttling electrons to oxygen in the electron transport chain, resulting in elevated 
cellular oxygen consumption (Callaway et al., 2004; Lindahl and Oberg, 1961; 
Visarius et al., 1997). Therefore, it is possible that MB may increase oxygen 
consumption and compensate for decreased activity of mitochondrial complexes. 
The other mechanism is related to its powerful antioxidant effects. For 
example, it inhibits superoxide, the most abundant oxygen radical generated in vivo, 
by accepting electrons from tissue oxidases (Kelner et al., 1988; Salaris et al., 1991). 
Another antioxidant action of MB is its inhibition of nitric oxide (Mayer et al., 1993). 
Nitric oxide can form the damaging peroxynitrite after reacting with superoxide. 
Therefore, MB administration could be very effective in preventing mitochondrial 
oxidative damage leading to neurodegeneration (Gonzalez-Lima et al., 1998). 
Therefore, we hypothesize that administration of MB in our optic neuropathy 
model may be of therapeutic value and effectively prevent the degeneration 
characterized by inhibition of mitochondrial function. 
 
1.6 EXPERIMENTAL GOALS 
In the first experiment (Chapter 2), a modified tetrazolium salt method was 
developed to demonstrate complex I enzymatic activity on brain homogenates and rat 
retina. This method relies on the reduction of tetrazolium salts by hydrogen ions 
released during oxidation to produce a colored formazan deposit on the tissue. 
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Quantitative analysis was done on the intensity of formazan deposited in the incubated 
sections. A strong linear relationship existed between the optical density and 
incubation time within the first 30 min for all section thicknesses. Therefore, this 
tetrazolium salt method is one way to demonstrate complex I activity quantitatively in 
our animal model. 
In the second experiment (Chapter 3), rotenone, a specific complex I inhibitor, 
was administered intravitreally in CBA/J mice to generate an animal model of optic 
neuropathy caused by defective complex I. The degeneration of the retina was 
demonstrated by a significant thickness reduction in the ganglion cell layer (GCL) 
with the rest of the retina layers relatively spared. This could be an effective in vivo 
animal model for exploring the mechanisms and treatment of neurodegenerative 
diseases as well as a model to study environmental involvement in neurodegenerative 
diseases. 
The third experiment (Chapter 4) investigated in detail the disease model at the 
cellular level. The maximal reduction of the retinal GCL thickness that occurred as a 
consequence of rotenone administration could be seen 24 hours later. Retinal nerve 
fiber layer thickness was reduced by 89% and the number of GCL cells was reduced 
by 21%. Cellular morphometric data (soma area, perimeter, and diameter) did not 
show overall differences, but there was a relative reduction in the proportion of larger 
cells. Therefore, the reduction in GCL thickness after 24 hours following rotenone 
microinjection could be accounted for by cell loss and nerve fiber shrinkage, but not 
by overall soma size change. 
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The fourth experiment (Chapter 5) explored a therapeutic intervention in the 
experimental model of optic neuropathy by intravitreal injection of MB along with 
rotenone. The rotenone-induced neurodegeneration, indicated in Experiment 3 by 
significant reductions in both the thickness and cell numbers (stereology 
measurements) of the retinal ganglion cell layer, was completely prevented by the 
injection of methylene blue along with rotenone. Possible mechanisms of MB were 
examined. The findings suggest that methylene blue may be a promising therapeutic 




Bailey SM, Pietsch EC, Cunningham CC (1999) Ethanol stimulates the production of 
reactive oxygen species at mitochondrial complexes I and III. Free Radical 
Biology and Medicine 27: 891-900. 
Barber DA, Rubin JW, Zumbro GL, and Tackett RL. (1995) The use of methylene 
blue as an extravascular surgical marker impairs vascular responses of human 
saphenous veins. Journal of thoracic and cardiovascular surgery 109: 21-29. 
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NQ, Miller JM, Storey E, 
Srivastava R, Rosen BR, and Hyman BT. (1993a) Neurochemical and 
histologic characterization of excitotoxic lesions produced by the 
mitochondrial toxin 3-nitropropionic acid. J.Neurosci. 13: 4192. 
Beal MF, Brouillet E, Jenkins BG, Henshaw R, Rosen B, and Hyman BT. (1993b) 
Age-dependent striatal excitotoxic lesions produced by the endogenous 
mitochondrial inhibitor malonate. J.Neurochem. 61: 1147-1150. 
Beal MF, Howell N, Bodis-Wollner I (1997) Mitochondria and free radicals in 
neurodegenerative diseases. New York: Wiley-Liss. 
Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochimi et 
Biophys Acta (BBA) - Bioenergetics 1366: 211-223. 
 26 
Bear MF, Connors BW, Pardiso MA (2005) The eye. In: Neuroscience: Exploring the 
Brain, 2nd Edition pp 281-312. Lippincott Williams & Wilkins. 
Besch D, Leo-Kottler B, Zrenner E, Wissinger B (1999) Leber's hereditary optic 
neuropathy: Clinical and molecular genetic findings in a patient with a new 
mutation in the ND6 gene. Graefe's Archive for Clinical and Experimental 
Ophthalmology 237: 745-752. 
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT 
(2000) Chronic systemic pesticide exposure reproduces features of Parkinson's 
disease. Nat Neurosci 3: 1301-1306. 
Bodansky O, Gutmann H (1947) Treatment of methemoglobinemia. J Pharmacol 46-
56. 
Bradberry SM (2003) Occupational methaemoglobinaemia. Mechanisms of 
production, features, diagnosis and management including the use of 
methylene blue. Toxicol Rev 22: 13-27. 
Brown MD, Voljavec AS, Lott MT, MacDonald I, Wallace DC (1992) Leber's 
hereditary optic neuropathy: A model for mitochondrial neurodegenerative 
diseases. FASEB J 6: 2791-2799. 
Brown MD, Wallace DC (1994) Spectrum of mitochondrial DNA mutations in Leber's 
hereditary optic neuropathy. Clin Neurosci 138-145. 
Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F (2004) Methylene 
blue improves brain oxidative metabolism and memory retention in rats. 
Pharmacol Biochem and Behav 77: 175-181. 
Callaway NL, Riha PD, Wrubel KM, McCollum D, Gonzalez-Lima F (2002) 
Methylene blue restores spatial memory retention impaired by an inhibitor of 
cytochrome oxidase in rats. Neurosci Lett 332: 83-86. 
Clifton J, Leikin JB (2003) Methylene blue. Am J Ther 10: 289-291. 
Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative 
disorders. Science 262: 689-695. 
Degli Esposti M (1998) Inhibitors of NADH-ubiquinone reductase: an overview. 
Biochimi et Biophys Acta (BBA) - Bioenergetics 1364: 222-235. 
 27 
Derom AF, Wallaert PC, Janzing HM, Derom FE (1993) Intraoperative identification 
of parathyroid glands with methylene blue infusion. Am J Surg 165: 380-382. 
DiMauro S. (2001) Lessons from mitochondrial DNA mutations. Cell & 
Developmental Biology 9: 397-405. 
Dowling JE (1987) The retina: an approachable part of the brain. Belknap Press. 
Ernster L, Dallner G, Azzone GG (1963) Differential effects of rotenone and amytal 
on mitochondrial electron and energy transfer. J Biol Chem 238: 1124-1131. 
Ernster L, Jalling O, Low H, Lindberg O (1955) Alternative pathways of 
mitochondrial DPNH oxidation, studied with amytal. Exptl Cell Res Suppl 3: 
124-132. 
Etteldorf JN (1951) Methylene blue in the treatment of methemoglobinemia in 
premature infants caused by marking ink; a report of eight cases. J Pediatr 38: 
24-27. 
Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of 
rotenone produces selective damage in the striatum and globus pallidus, but 
not in the substantia nigra. Brain Res 753: 157-162. 
Floyd RA, Schneider J, Dittmer DP (2004) Methylene blue photoinactivation of RNA 
viruses. Antiviral Research 61: 141-151. 
Genova ML, Pich MM, Bernacchia A, Bianchi C, Biondi A, Bovina C, Falasca AI, 
Formiggini G, Castelli GP, Lenaz G (2004) The Mitochondrial Production of 
Reactive Oxygen Species in Relation to Aging and Pathology. Ann NY Acad 
Sci 1011: 86-100. 
Gonzalez-Lima F, Valla J, Jorandby L (1998) Cytochrome oxidase inhibition in 
Alzheimer's disease. In: Cytochrome oxidase in neuronal metabolism and 
Alzheimer's disease (Gonzalez-Lima F, ed), pp 171-200. New York: Plenum 
Press. 
Greenamyre JT, Sherer TB, Betarbet R, Panov AV (2001) Complex I and Parkinson's 
disease. IUBMB Life 52: 135-141. 
Gyllensten U, Wharton D, Josefsson A, and Wilson AC. (1991) Paternal inheritance of 
mitochondrial DNA in mice. Nature 352: 255-257. 
 28 
Hassan HM, Fridovich I (1979) Intracellular production of superoxide radical and of 
hydrogen peroxide by redox active compounds. Archives of Biochemistry and 
Biophysics 196: 385-395. 
Hatefi Y (1985) The mitochondrial electron transport and oxidative phosphorylation 
system. Annual Review of Biochemistry 54: 1015-1069. 
Heikkila RE, Nicklas WN, Vyas I, Duvoisin RC (1986) Dopaminergic toxicity of 
rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic 
administration to rats: implication for the mechanism of 1-methyl-4-phenyl-
1,2,3,6,-tetrahydropyridine toxicity. Neurosci Lett 62: 389-394. 
Howell N (1998) Leber hereditary optic neuropathy: Respiratory chain dysfunction 
and degeneration of the optic nerve. Vision Res 38: 1495-1504. 
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing 
neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the 
metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective 
toxicity. Proc Natl Acad Sci U S A 82: 2173-2177. 
Kelner MJ, Bagnell R, Hale B, Alexander NM (1988) Potential of methylene blue to 
block oxygen radical generation in reperfusion injury. Basic Life Sci 49: 895-
898. 
Kupfer A, Aeschlimann C, Cerny T (1996) Methylene blue and the neurotoxic 
mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50: 249-252. 
Kupfer A, Aeschlimann C, Wermuth B, Cerny T (1994) Prophylaxis and reversal of 
ifosfamide encephalopathy with methylene-blue. Lancet 343: 763-764. 
Lindahl PE, Oberg KE (1961) The effect of rotenone on respiration and its point of 
attack. Exptl Cell Research 23: 228. 
Luft R (1994) The development of mitochondrial medicine. Proc Natl Acad Sci 91: 
8731-8738. 
Luft R, Ikkos D, Paknueru G, Ernster L, Afzelius B (1962) A case of severe 
hypermetabolism of nonthyroid origin with a defect in the maintenance of 
mitochondrial respiratory control: a correlated clinical, biochemical, and 
morphological study. J Clin Invest 41: 1776--1804. 
 29 
Manhes H, Shulman A, Haag T, Canis M, Demontmarin JL (2004) Infertility due to 
diseased pelvic peritoneum: laparoscopic treatment. Gynecol Obstet Invest 37: 
191-195. 
Martinez JLJr, Jensen RA, Vasquez BJ, McGuinness T, McGaugh JL (1978) 
Methylene blue alters retention of inhibitory avoidance responses. Physiol 
Psychol 6: 387-390. 
Mayer B, Brunner F, Schmidt K (1993) Inhibition of nitric oxide synthesis by 
methylene blue. Biochem Pharmacol 45: 367-374. 
Naylor GJ, Maton B, Hopwood SE, Watson Y (1986) A two-year double-blind 
crossover trial of the prophylactic effect of methylene blue in manic-depressive 
psychosis. Biol Psychiatry 21: 915-920. 
O'Leary JL, Petty J, Harris AB, Inukai J (2005) Supravital staining of mammalian 
brain with intra-arterial methylene blue followed by pressurized oxygen. Stain 
Technology 43: 197-201. 
Peter C, Hongwan D, Kupfer A, Lauterburg BH (2000) Pharmacokinetics and organ 
distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56: 
247-250. 
Raichle ME, Gusnard DA (2002) Appraising the brain's energy budget. Proc Natl 
Acad Sci USA 10237-10239. 
Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, Singer TP (1991) 
Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with 
the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 
56: 1184-1190. 
Reid CR (1999) Vision. In: Fundamental Neuroscience (Michael J.Zigmond, Floyd 
E.Bloom, Story C.Landis, James L.Roberts, Larry R.Squire, eds), pp 821-851. 
San Diego: Academic Press. 
Richardson KC (2005) The fine structure of autonomic nerves after vital staining with 
methylene blue. Anatomical Record 164: 359-377. 
Richter C (1992) Reactive oxygen and DNA damage in mitochondria. Mutat Res 249-
255. 
 30 
Salaris SC, Babbs CF, Voorhees III (1991) Methylene blue as an inhibitor of 
superoxide generation by xanthine oxidase: A potential new drug for the 
attenuation of ischemia/reperfusion injury. Biochem Pharmacol 42: 499-506. 
Schapira AHV (1998) Human complex I defects in neurodegenerative diseases. 
Biochimi et Biophys Acta (BBA) - Bioenergetics 1364: 261-270. 
Sherman J and Kleiner L. (1994) Visual system dysfunction in Leber's hereditary optic 
neuropathy. Clinical Neuroscience 2: 121-129. 
Shulman RG, Hyder F, Rothman DL (2003) Cerebral metabolism and consciousness. 
Crit Rev Biol 326: 253-273. 
Singer TP, Ramsay RR (1990) Mechanism of the neurotoxicity of MPTP. An update. 
FEBS Lett 274: 1-8. 
Singer TP, Ramsay RR (1994) The reaction sites of rotenone and ubiquinone with 
mitochondrial NADH dehydrogenase. Biochimi et Biophys Acta (BBA) - 
Bioenergetics 1187: 198-202. 
Storey BT. (1980) Inhibitors of energy-coupling site 1 of the mitochondrial respiratory 
chain. Pharmac.Ther. 10: 399-406. 
Storey E, Hyman BT, Jenkins BT, Brouillet E, Miller JM, Rosen BR, and Beal MF. 
(1992) MPP produces excitotoxic lesions in rat striatum due to impairment of 
oxidative metabolism. J.Neurochem. 58: 1975-1978. 
Stryer L (1999) Biochemistry. New York: W. H. Freeman and Company. 
Valla J, Berndt JD, Gonzalez-Lima F (2001) Energy hypometabolism in posterior 
cingulate cortex of Alzheimer's patients: Superficial laminar cytochrome 
oxidase associated with disease duration. J Neurosci 21: 4923-4930. 
Visarius TM, Stucki JW, Bernhard H (1997) Stimulation of respiration by methylene 
blue in rat liver mitochondria. FEBS Letters 412: 157-160. 
Voet D, Voet JG (1995) Biochemistry. John Wiley & Sons, Inc. 
Wainwright M, Crossley KB (2002) Methylene Blue--a therapeutic dye for all 
seasons? J Chemother 14: 431-443. 
Wallace DC, Brown MD, and Lott MT. (1999) Mitochondrial DNA variation in 
human evolution and disease. Gene 238: 211-230. 
 31 
Wassle H, Boycott BB (1991) Functional architecture of the mammalian retina. 
Physiol Rev 71: 447-480. 
Wieding JU, Hellstern P, and Kohler M. (1993) Inactivation of viruses in fresh-frozen 




Chapter 2: Histochemistry of mitochondrial complex I activity  
 
2.1 ABSTRACT 
Mitochondrial dysfunction is associated with neurodegenerative diseases. 
Mitochondrial complex I (NADH dehydrogenase) is the first complex in the electron 
transfer chain of mitochondria. Complex I deficiency has been identified in Leber's 
hereditary optic neuropathy, Parkinson's disease, and dystonia. We propose to use 
rotenone, a specific complex I inhibitor, to generate an animal model of optic 
neuropathy that is known to be caused by defective complex I. The objective of this 
study is to develop a reliable histochemical measurement of complex I activity to 
assess the neurodegeneration of the retina and the optic nerve, as well as other tissues 
of the central nervous system. A modified tetrazolium salt method was used to 
demonstrate complex I enzymatic activity on rat brain homogenates and rat retina. 
This method relies on the reduction of tetrazolium salts by hydrogen ions released 
during oxidation to produce a colored formazan deposit on the tissue. Quantitative 
analysis was done on the intensity of formazan deposited on the incubated sections. A 
linear relationship existed between the optical density and incubation time within the 
first 30 min for all of the section thicknesses. The brain homogenate standards 
incubated for 25 min showed an almost perfect linear relationship between the optical 
density and the tissue thickness (R2 = 0.99). The intensity of the two darkest layers in 
the retina is within the optical density range of the standards. This tetrazolium salt 
method is a way to demonstrate complex I activity quantitatively in our animal model. 
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2.2 INTRODUCTION 
Mitochondria are cytoplasmic organelles and the site of cellular respiration 
(aerobic metabolism) in almost all eukaryotes. Mitochondrial complexes are a number 
of proteins and protein complexes that are located in the inner membrane and involved 
in the process called electron transport. The major role of the electron transport chain 
(ETC) system is to take energy from nicotine adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) in the matrix and convert energy to a form that can be 
used to phosphorylate ADP, producing ATP. Complexes I and II collect electrons and 
transfer them to ubiquinone (coenzyme Q10). The electrons then move sequentially to 
complex III, cytochrome c, complex IV, and finally, to oxygen, which is the terminal 
electron acceptor. The hydrogen proton, which is transported together with the 
electron through the inner mitochondrial membrane, produces an electrochemical 
proton gradient that stores potential energy. Complex V uses energy stored in the 
proton gradient to condense ADP with inorganic phosphate into ATP, a process called 
oxidative phosphorylation (Voet and Voet, 1995). 
A dysfunctional mitochondrial electron transport chain decreases ATP 
production and accelerates the generation of free radicals. Mitochondrial dysfunction 
is associated with neurodegenerative diseases. For example, the electron transport 
Complex I deficiency, either specific or associated with other respiratory chain 
defects, has been identified in Leber's hereditary optic neuropathy, Parkinson's 
disease, and dystonia (Schapira, 1998). Reliable methods for measuring the function 
of mitochondrial complexes in the nervous system are essential and of great use in 
investigating mitochondrial involvement in these neurodegenerative diseases. 
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Inhibitors of mitochondrial complexes are used to generate animal models of 
neurodegenerative diseases. For example, sodium azide, a complex IV inhibitor, is 
used in an animal model of Alzheimer’s disease, because these patients have a 
systemic inhibition of complex IV (Bennett and Rose, 1992). Systemic administration 
of rotenone, a specific complex I inhibitor, has been used to model Parkinson’s 
disease, because nigrostriatal neurons exhibit an enhanced toxicity following a chronic 
administration of large systemic doses of rotenone (Betarbet et al., 2000). We propose 
to use rotenone, a specific complex I inhibitor, injected in the eye, to generate an optic 
neuropathy model that is known to be caused by defective complex I. Therefore, the 
objective of this study is to develop a reliable measurement of complex I activity to 
assess the neurodegeneration of the retina and the optic nerve, as well as tissues of 
other central nervous system components. 
Mitochondrial complex I (NADH dehydrogenase) is the first complex in the 
electron transfer chain of mitochondria and catalyzes the transfer of electrons from 
NADH to coenzyme Q (CoQ):  
 
NADH + CoQ + H+  NAD+ + CoQH2    (Scheme 2.1) 
 
In addition to transferring electrons to reduce coenzyme Q, this complex also 
translocates protons, helping to provide the electrochemical potential used to produce 
ATP. It is the largest complex in the ETC; the mammalian enzyme contains 43 
separate protein subunits (Greenamyre et al., 2001; Robinson, 1998; Schapira, 1998; 
Voet and Voet, 1995).  
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Complex I enzymatic activity can be measured quantitatively and reliably by 
using histochemical and imaging techniques (Barry et al., 1993; Murray et al., 1988; 
Sims et al., 1974; Van Noorden and Frederiks, 1992). Tetrazolium salt methods are the 
most frequently used methods in the enzyme histochemical techniques for the 
demonstration of the activity of dehydrogenases, reductases, and oxidases (Van 
Noorden and Frederiks, 1992). Tetrazolium salts are colorless or yellow and water-
soluble; they can be reduced metabolically to the highly colored water-insoluble 
microcrystalline deposits called formazans by accepting hydrogen released from the 
substrate through enzyme action.  
The mechanism of the tetrazolium salt reaction chain consists of several 
electron transfers. The first step is the enzyme-mediated electron transfer from one 
substrate to the other. Then, the reduced coenzyme NAD+ or flavoprotein reduces the 
tetrazolium salt to its formazan deposit which is colored, and finely granular (see 
Scheme 2.2).  
Nitro BT (Oxidized) + NADH  Formazan (Reduced) + NAD (Scheme 2.2) 









After they are reduced by accepting hydrogen they become an insoluble colored 








The intensity of the formazan color can be measured quantitatively, providing 




All materials were purchased from Sigma-Aldrich, St. Louis, MO. 
 
2.3.2 Sample preparation 
All experimental procedures were performed in accordance with NIH 
guidelines and were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Texas at Austin. Brain tissue standards were prepared 
based on the procedure of Gonzalez-Lima et al. (1998). Briefly, the brains of male 
Sprague-Dawley rats that had not been perfused or exposed to anesthetics were used. 
After decapitation the unfixed brains were quickly harvested and stored at 4°C in 
sodium phosphate buffer (pH, 7.4) until all brains were collected. Then the tissue was 
transferred to chilled clear glass homogenizer tubes kept on ice and homogenized by 
hand for about 2-3 min or until uniform. Aliquots of the brain tissue were transferred 
to microtubes and then centrifuged at low speed (1000 rmp, 5-10 sec). The brain 
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homogenate, along with the microtubes, was then frozen in isopentane and stored at -
40 °C.  
 
2.3.3 Histochemical reactions 
In order to prepare tissue standards, brain tissue homogenate was frozen inside 
plastic tubes. Then the tissue was removed, mounted, and sectioned at 10, 20, 40, 60, 
and 80 µm on a cryostat on the same day they were to be used in histochemical 
procedures. Sections of rat eyes that were previously cut at 40 µm anterior-posteriorly 
were also prepared. Slides with fresh-frozen sections were put into three consecutive 
baths of 0.1 M sodium phosphate buffer solution (PBS) with 10% (w/v) sucrose for 5 
min each to increase adherence of the tissue to the slide. The three baths were filled at 
the same time so they were warmed up gradually to room temperature. After rinsing in 
0.1M PBS, slides were incubated at 37oC in the dark for 15, 25, 35, and 45 min with 
agitation in 0.1M PBS containing NADH (Sigma, 1 mg/ml), nitroblue tetrazolium 
(Sigma, 1.33 mg/ml), and sodium azide (Sigma, 0.065 mg/ml). Sodium azide was used 
to inhibit cytochrome oxidase (complex IV) (Gonzalez-Lima and Cada, 1998). A 
detailed protocol of complex I staining appears in Appendix. 
 
2.3.4 Microscopic imaging analysis 
Optical densitometry measurements were used to quantify complex I 
histochemistry. A high resolution video camera (Javelin JE-7442) was mounted on an 
Olympus light microscope (model BX40) to capture the images which were then 
transmitted to a frame grabber in a computer where the image was digitized. Image 
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analysis was completed using JAVA (Jandel Scientific) imaging software. The same 
microscope lamp intensity level was maintained throughout the study. 
The gray levels of a standard calibration strip with a range of known optical 
densities were measured, and a best-fit mathematical equation (optical density as a 
function of gray levels) was created based on the gray levels and the optical density 
measurements. The equation was then applied on all the gray levels measured from the 
imaging processing system to convert them into values of optical density which is 
proportional to brightness. All experimental values were within the range of optical 
densities covered by the standards. 
 
2.4 RESULT 
The presence of complex I in the histochemical preparation appeared as a 
shade of purple. The cross section of the rat retina showed distinctive laminar structure 
in the staining (Figure 2.1). The inner segment layer and the ganglion cell layer were 
fairly dark purple, indicating the overwhelming complex I activity, while the inner 
plexiform layer was lighter. The inner and outer nuclear layers, which are mostly 
composed of cell bodies, showed pinkish color.  
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Figure 2.1 A) Cross-section of rat eye. B) Cross-section of rat retina at higher 
magnification. Complex I staining, 40 µm sections. 
 
 
A linear relationship existed between the optical density and incubation time 
within the first 30 min for all section thicknesses. The darkness of the stain on the 
brain homogenate increased with the section thickness (Figure 2.2). Since all sections 
with different thicknesses reached their saturation of staining around 35 min, a 25 min 
incubation time was optimal because it was just below the saturation level. The values 
of optical density for the brain homogenate standards, incubated for 25 min, were 
plotted as shown in Figure 2.3, and resulted in an almost perfect linear relationship 





Figure 2.2 Effect of incubation time on optical density of rat brain homogenates of 
10, 20, 40, 60, and 80 µm thickness. 
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Figure 2.3 Effect of section thickness on optical density of standard rat brain 
homogenate sections incubated for 25 min at 37oC. The optical density 
increases linearly with increased thickness of the standards. 
 


























To estimate the range of optical density in the retina, data were taken from the 
40 µm inner segment layer and the ganglion cell layer, which appeared to be the two 
darkest layers in the retina (Figure 2.4). The optical density values were below 0.68, 
well within the optical density range of the standards (Figure 2.2).  
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Figure 2.4 Effect of incubation time on optical density of the inner segment layer 
and the ganglion cell layer of the rat retina.  
 





























Mitochondrial complex I activity was revealed histochemically using a 
modified procedure based mainly on the techniques of Murray et al. (1988) and Barry 
et al. (1993). The enzymatic activity was assessed quantitatively from the intensity of 
formazan deposited on the incubated tissue sections. There was a linear relationship 
between the optical density and the incubation time within 35 min, and a strong linear 
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relationship between the optical density and various thicknesses of standards after 
incubation for 25 min. 
We do not know why the retinal sections stained both pink and blue by this 
procedure, but it has been reported that most tetrazolium salts give red formazans in 
normal tissue, whereas blue formazans occur in ischemic tissues (Hoyer and Lyon, 
1991). One type of monotetrazolium salt always gives blue formazans, but it is not 
commercially available (Hoyer and Lyon, 1991). It appeared from our slides that the 
cell bodies were mostly pink and the neuropil were mostly blue. 
An exogenous electron carrier such as menadione or (1-methoxy) phenazine 
methosulfate can be added to the incubation medium in order to speed up the electron 
transfer to the tetrazolium salt, because the redox potential of coenzyme and 
tetrazolium salt do not have a fast electron flow from coenzyme to tetrazolium salt. 
The choice of these intermediate electron carriers depends on the localization of the 
dehydrogenase of interest (Van Noorden and Frederiks, 1992). For mitochondrial 
enzymes, phenazine methosulfate should be chosen because 1-methoxyphenazine 
methosulfate cannot pass the mitochondrial membrane (Kugler, 1982). In our study, 
the stain appeared sufficient without the use of any exogenous electron carrier, 
therefore it was not included in the protocol. 
An autoradiographic assay has been developed to study complex I using the 
binding of [3H]dihydrorotenone (Talpade et al., 2000). One of the limitations of this 
autoradiographic method is that it only assesses the enzyme availability for binding 
the chemical and not the enzymatic activity or function of complex I. Non-specific 
binding is another problem with this method. 
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The histochemical assay of complex I activity can be specifically inhibited by 
rotenone. Rotenone is an irreversible and specific complex I inhibitor (Lindahl and 
Oberg, 1961) that we propose to use in our animal model. Jung et al., (2002) used 
similar reagents and concentrations of incubation solution to those in our protocol, and 
tested the specificity of complex I in the presence of rotenone. The enzyme activity 
decreased significantly after a highly saturating concentration of rotenone (60 µΜ) 
was added. The activity did not decrease in the presence of the inhibitors of other 
complexes of the ETC.  
In summary, the tetrazolium salt method is the most commonly used method to 
evaluate complex I enzymatic activity. The demonstration of complex I relies on the 
reduction of tetrazolium salts by hydrogen ions released during oxidation through 
enzyme activity to produce colored formazan deposit on the tissue. This enables the 
quantitative assay of complex I activity using densitometric analysis on the intensity 
of formazan deposited on the incubated sections of any tissue.  
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Chapter 3: Effects of Pesticide Rotenone in the Mouse Retina: A 




To help fulfill the need for developing effective in vivo animal models for 
exploring the mechanisms and treatment of neurodegenerative diseases, we developed 
a mouse model of optic neuropathy caused by mitochondrial complex I dysfunction by 
intravitreal administration of rotenone, a complex I inhibitor, in CBA/J mice. Retinal 
thickness was measured in sections stained histochemically for complex I enzymatic 
activity. The retinal ganglion cell layer of eyes injected with rotenone was 
significantly thinner than that of the control eyes injected with the vehicle, dimethyl 
sulfoxide, at 1, 24, and 48 h survival times. The largest reduction in thickness was 
41% at 24 h post-injection. This effect is consistent with the degeneration of retinal 
ganglion cells in Leber’s hereditary optic neuropathy. This is the first animal model of 
optic neuropathy resulting from mitochondrial dysfunction, and it could be used as an 
efficient and convenient way to test new treatments for mitochondrial 
neurodegenerative diseases. This model could also be used to study environmental 




There is a compelling need to develop effective animal models for exploring 
the mechanisms and treatment of neurodegenerative diseases. The objective of this 
study was to create a mouse model of optic neuropathy caused by mitochondrial 
dysfunction using rotenone, a naturally occurring pesticide that inhibits mitochondrial 
complex I (Degli Esposti, 1998; Ernster et al., 1963; Lindahl and Oberg, 1961). 
Mitochondrial dysfunction has been identified in neurodegenerative disorders, 
including Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease (Valla et 
al., 2001; Brown and Wallace, 1994; Betarbet et al., 2000), and a role for the 
mitochondrial electron transport chain and oxidative phosphorylation is gathering 
increasing experimental support. For example, increasing evidence shows that Leber’s 
hereditary optic neuropathy (LHON) is a neurodegenerative disease linked to 
mitochondrial complex I dysfunction (Brown and Wallace, 1994; Howell and Mackey, 
1998). LHON has come to be regarded as a model disease for mitochondrial 
neurodegenerative diseases because “LHON can now be understood as a cooperative 
interplay of genetic, environmental, and physiological factors” (Brown et al., 1992). 
Complex I is an integral membrane protein complex composed of 43 separate 
protein subunits in mammals (Greenamyre et al., 2001; Robinson, 1998; Schapira, 
1998), seven of which (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) are encoded by 
mitochondrial DNA (mtDNA) (Walker et al., 1992). Three primary mtDNA point 
mutations have been linked to LHON and account for 90-95% of the occurrence of the 
disorder (Brown and Wallace, 1994; Besch et al., 1999). The three primary mutations 
are at nucleotide positions 11778/ND4, 3460/ND1 and 14484/ND6, all of which affect 
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complex I. In addition, at least 16 different secondary mtDNA mutations have been 
found (Brown and Wallace, 1994; Brown, 1999). LHON is the most common cause of 
blindness in otherwise healthy young men (Schapira, 1998). It is a maternally 
inherited disease which classically manifests as acute or subacute onset with bilateral 
central vision loss associated with the degeneration of the retinal ganglion cell layer 
and the optic nerve (Howell and Mackey, 1998; Brown et al., 1992).  
To date, no effective treatment is available for mitochondrial 
neurodegenerative diseases, including LHON, and to our knowledge, there were no in 
vivo animal models for optic neuropathy caused by mitochondrial dysfunction. Thus, 
there was a great need to develop an animal model to test candidate treatments.  
Inhibition of complex I activity in retinal neurons should lead to dysfunctional 
mitochondria, which could be potentially a good model of complex I-related optic 
neuropathy. Since the retina is part of the central nervous system, this could also be an 
in vivo model for neurodegenerative diseases in general. One of the complex I 
inhibitors is rotenone, a natural substance found in the stems and roots of certain 
tropical plants. It is a very commonly used compound for treating lakes and has been 
used in numerous lakes and reservoirs to remove unwanted fish species and restore 
traditional fisheries. In addition, it is used as a garden insecticide to control chewing 
insects. Rotenone is a specific and irreversible inhibitor of complex I through its firm 
binding to complex I (Ernster et al., 1963). To create a neurodegenerative animal 
model using rotenone administration in the eye is not only important for optic 
neuropathic processes but also can be of environmental significance. 
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3.3 MATERIALS AND METHODS 
3.3.1 Subjects and anesthetics 
Male CBA/J mice (25-44 g, N = 32) were used in this study. The mice were 
anesthetized by an intraperitoneal injection of a mixture of ketamine hydrochloride (45 
mg/kg), xylazine hydrochloride (9 mg/kg), and acepromazine (1.5 mg/kg).  
 
3.3.2 Intravitreal injection  
Rotenone was administered into one eye of each mouse via intravitreal 
injection, while the vehicle, dimethyl sulfoxide (DMSO), was injected into the other 
eye of each mouse as a within-subject control. In a pilot study with 7 mice, several 
doses of rotenone were tested (0.065 to 0.2 mg/kg). The largest dose (0.2 mg/kg) 
appeared more effective in reducing retinal thickness and it was thus selected for 
subsequent study. One eye of each mouse was intravitreally injected with 0.5 µl 
rotenone (31.18 mM) in dimethyl sulfoxide (DMSO) over 2 min using a 
microinjection pump (CMA microdialysis AB, North Chelmsford, MA). The 
intravitreal injection point was just behind the limbus of the cornea in the superior and 
temporal quadrant of the eye to give access to the vitreous body without damaging the 
retina. A small sclerotomy was first performed using a fine needle (30 gauge). Then 
the injections were administered via 30-G blunt-ended dental injection needles 
(Monoject®, Sherwood Medical Company, Norfolk, NE) connected via polyethylene 
tubing to 10-µl Hamilton microsyringes (Hamilton Company, Reno, NV) powered by 
the microinjection pump. After the injections were completed, the needles were left in 
place for an additional 40 sec to allow for diffusion away from the needle tip and to 
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avoid any efflux of fluid through the injection site (Salinas et al., 1997). The other eye 
received the same volume and rate of injection of the vehicle DMSO only. Mice (N = 
25) were randomly divided into 3 survival time groups following the injection (1 h, 24 
h, and 48 h following injection); an additional control group received no injection. At 
the end of each survival time, the animals were decapitated and the eyeballs were 
rapidly removed, frozen in isopentane, and sectioned at 20 µm in a cryostat (Reichert-
Jung) at –18oC. 
 
3.3.3 Complex I histochemistry 
Sections were stained for complex I activity following a well-documented 
method using tetrazolium, which has been well-documented in brain and spinal cord 
(Barry et al., 1993; Murray et al., 1988; Jung et al., 2002), and we validated it for the 
retina (Chapter 2). Tetrazolium salts are colorless or yellow and water-soluble; they 
can be reduced metabolically to the highly colored water-insoluble microcrystalline 
deposits called formazans by accepting hydrogen released from the substrate (NADH) 
through enzyme action which is, in this case, complex I (see Chapter 2). Using the 
optimal conditions explained in Chapter 2, fresh-frozen sections were incubated at 
37oC for about 20 min with agitation in phosphate buffer containing NADH (Sigma, 1 
mg/ml), nitroblue tetrazolium (Sigma, 1.33 mg/ml), and sodium azide (Sigma, 0.065 
mg/ml) for inhibiting complex IV activity (Gonzalez-Lima and Cada, 1998). Sections 




3.3.4 Image analysis 
Using a microscopic image-processing system which included an Olympus 
BX40 microscope (Olympus America; Lake Success, NY), a CCD camera (Javelin 
Electronics; Torrance, CA), a Targa M8 image capture board and JAVA imaging 
software (Jandel Scientific; Corte Madera, CA), thickness was measured in the GCL, 
the inner plexiform layer (IPL), and the whole retina, from eye sections stained for 
complex I activity. To avoid the possible confound of retinal thickness differences by 
location, data were always taken from the same position, the center of the retina at 
about twice the diameter of the optic disc away from the center of the optic nerve. 
About 20 measurements were taken with equal intervals in distance along the cross-
section of the retina within the screen of the monitor, and from both sides of the optic 
nerve.  
 
3.3.5 Statistical analysis 
A repeated measures analysis of variance followed by multiple comparisons 
and tests for simple effects was used to evaluate group differences at p < 0.05. 
Statistical differences in thickness of the GCL, IPL and the whole retina in rotenone 
treated eyes vs. the vehicle DMSO treated eyes in different survival times were 
evaluated. A two-tailed t-test at p < 0.05 was used with paired samples from both eyes 
in each subject from the 24 h group, to further test the significance of differences in 
IPL thickness between the rotenone-treated eye of each subject and its vehicle DMSO-
treated control eye. The “n” equals number of mice with pairs of rotenone treated and 
control eyes, and pairs of eyes of the control subjects that received no injection. 
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3.4 RESULTS 
The complex I staining of the cross-sectional mouse retina at 24 h following 
rotenone injection is shown in Figure 3.1. The neuropil (dendrites and axons) could be 
distinguished from the cell bodies by the color of the stain, blue for neuropil and pink 
for cell bodies. The different patterns of each retinal layer allowed its delineation from 
other layers. However, the retinal nerve fiber layer (RNFL) is too thin to be 
distinguished from the ganglion cell layer, and it was included in the GCL for the 
thickness measurement. It appears clearly that the GCL thickness of the rotenone 
treated eyes (Figure 3.1 A) is thinner than that of the DMSO treated control eyes 
(Figure 3.1 B). 
 
Figure 3.1 Cross section of the retina with complex I staining in rotenone treated (A) 
and DMSO treated control (B) of 24 h post-injection group. The 
thickness of the ganglion cell layer (GCL) is indicated by the distance 
between two arrows. The inner plexiform layer (IPL) was delineated 
based on the blue stain. Complex I histochemistry resulted in blue 
staining of the IPL, which delineated this layer from other retinal layers 
(not shown in black and white photo). The entire unit bar length 










Results (Table 3.1) on the GCL thickness showed that the thickness of the 
retinal ganglion cell layer (GCL) of the rotenone treated eyes was significantly 
reduced compared to that of the DMSO control eyes at 1 h (n = 8, p < 0.001), 24 h (n 
=10, p < 0.001), and 48 h survival times (n = 5, p = 0.02). Among the three groups the 
largest reduction of the GCL thickness was 41% at 24 h post-injection (Figure 3.1 and 
3.2). Using multiple comparisons followed by Bonferroni correction, no difference in 
the thickness of retinal GCL was found between non-injected and DMSO treated 
control eyes across different post-injection time groups. However, within the rotenone 
treated groups, the GCL of the 1 h and 24 h post-injection groups was significantly 
thinner in comparison to the non-injected group (p = 0.028 and 0.002 respectively). 
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Table 3.1 Retinal thickness (mean ± standard error, microns) of different post-
injection groups: non-injection (NI) control group, 1 h, 24 h, 48 h. GCL= 
ganglion cell layer, IPL= inner plexiform layer, WH= whole retina. * 
Significant (P<0.05) difference between rotenone and control groups. 
 
  Control Rotenone 
Group N GCL IPL WH  GCL IPL WH 
NI 3 26.25±5.63 32.93±8.01 87.89±13.3  25.79±6.04 33.28±6.45 91.74±10.93 
1 h 8 23.92±2.37 37.58±2.33 100.01±8.5  17.05±0.9* 38.75±2.31 97.54±6.24 
24 h 9 23.83±1.97 36.25±2.52 95.66±7.20  13.57±1.0* 30.86±1.6*  76.53±3.59* 
48 h 5 23.71±1.79 31.95±1.55 89.26±4.63  19.16±1.7* 31.64±1.56 84.83±5.55 
 
 
For retinal layers other than the GCL, the rotenone treated eyes also showed 
significantly reduced thickness compared to the DMSO treated control eyes in the 24 h 
post-injection group in both the inner-plexiform layer (IPL, p = 0.042) and the whole 
retina (p = 0.025) when using the global error terms pooled from all the time groups. 
For testing the effect of rotenone on retinal layers other than the GCL and IPL, the 
thickness of the GCL and IPL was subtracted from that of the whole retina to provide 
a measure of retinal thickness without the effect of the GCL and IPL. No significant 
statistical differences were found in the rest of the retina. 
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Figure 3.2 Percent of reduction (mean ± standard error bars) in the ganglion cell 
layer (GCL) thickness of rotenone vs. DMSO (control) treated eyes in 
different post-injection time groups: non-injection (NI), 1 h, 24 h and 48 
h groups. 
Group




















The first animal model of optic neuropathy caused by mitochondrial 
dysfunction was established through intravitreal injection of rotenone, a specific 
inhibitor of mitochondrial complex I. The retinal ganglion cell layer was significantly 
reduced at 1, 24, and 48 h following injection, with the largest reduction of 41% at 24 
h post-injection. This effect is consistent with the degeneration of retinal ganglion 
cells in Leber’s hereditary optic neuropathy. The retina is derived from the 
diencephalons; therefore, it is a part of the central nervous system. A 
neurodegenerative animal model developed in the eye not only provides a relatively 
independent simple in vivo central nervous system that does not rely on the function of 
other CNS regions, but also permits easy access for various research techniques and 
for drug delivery.  
Since neurons (e.g., retinal ganglion cells) have very limited capacity for 
regeneration, the “recovery” phenomenon that appeared at 48 h in GCL thickness 
reduction may be explained by the regeneration of the neurites (dendrites and axons) 
of the ganglion cells and displaced amacrine cells, and/or the generation or 
regeneration of glial cells in this layer. Only about 60% (Drager and Olsen, 1981) or 
41% (Jeon et al., 1998) of total cells in the mouse GCL are ganglion cells (Jeon et al., 
1998); the rest of the cells are displaced amacrine cells and glial cells. The displaced 
amacrine cells can comprise up to 50% in rats (Perry, 1981), and 60% in mouse (Jeon 
et al., 1998), of the total cells in the GCL. It has been demonstrated that retinal 
ganglion cells in the retinas of adult mammals have the capacity to regenerate neurites 
after they are injured in vivo (So and Aguayo, 1985) and in vitro (Takano et al., 2002; 
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Thanos and Thiel, 1990). However the “recovery” phenomenon that appeared here 
needs further evaluation with an increased number of subjects (n = 5, here). 
A tetrazolium salt histochemical method was used in this study to demonstrate 
complex I activity in the retina. However, because tissue shrinkage occurred 
profoundly in the GCL and to a less degree in the IPL at 24  h post-injection, the 
phenomenon of the darker staining intensity that appeared in the two layers of most 
rotenone-treated sections compared to the control may not simply indicate elevated 
level of complex I activity. In fact, the intended use of the complex I histochemistry 
technique here was to delineate the complete boundary of the retinal ganglion cell 
layer and the nerve fiber layer, rather than to provide quantitation of complex I 
activity. 
Mitochondrial complex I staining is more suitable than other common 
histological methods, such as Nissl staining, for two reasons. First, rotenone is a 
selective complex I inhibitor, and complex I staining is specific to the effect of 
rotenone. Second, the neuropil surrounding the cell bodies in the retinal ganglion cell 
layer (GCL), especially the retinal nerve fibers at the inner surface of the GCL, is 
visible only in complex I stained tissues. Therefore, it provides information not shown 
with other techniques. 
The results of this study showed that rotenone administration to the eye caused 
a loss of tissue (most likely neurons and their processes) in both the GCL and the IPL. 
The GCL contains optic nerve fibers and the retinal ganglion cell bodies, while the 
IPL contains dendrites of retinal ganglion cells and neurites of bipolar cells and 
amacrine cells. In the rodent retina, just like the human retina, small and medium-
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sized ganglion cells predominate in the central retina, and large cells locate mostly in 
the peripheral regions (Kageyama and Wong-Riley, 1984). Data were taken from the 
center of the retina due to the vulnerability of small ganglion cells in optic 
neuropathies (Kageyama and Wong-Riley, 1984). The damage of the retinal ganglion 
cells in the central retina of this model is consistent with the retinal pathological 
manifestation seen in LHON patients (Beal et al., 1997; Brown et al., 1992; Howell, 
1998).  
The etiology of LHON is complex, which is indicated by its remarkable 
features. For example, there is a highly variable penetrance (the proportion of 
individuals of a particular genotype that express its phenotypic effect in a given 
environment), even within the same family with the same pathogenic homoplasmic 
mutation (all mtDNA copies are mutated) (Howell, 1998). Transmission of a LHON 
mutation from one generation to another does not always correlate with transmission 
of the disease; many family members of LHON patients harbor the same mutation, but 
they are visually asymptomatic (Riordan and Harding, 1995). The primary mtDNA 
mutation is not sufficient for the manifestation of the optic neuropathy (Howell and 
Mackey, 1998). The disparity between the phenotypic expression and the genotype 
suggests that the genetic factor is not the sole factor; thus the etiology of the disease 
may not be simply one of genetic defects but may be exacerbated by or caused by 
environmental toxic agents inhibiting mitochondrial respiration (Berndt et al., 2001). 
This is supported by the work of Carelli et al. (2002) who have shown that 
environmental factors are needed to express the neuropathy. This idea is also 
supported by recent toxicological studies of Parkinson’s disease, which indicate links 
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to rotenone (Betarbet et al., 2000). More attention should be given to the contribution 
of exposure to environmental toxins, including pesticides, to the incidence of 
mitochondrial neurodegenerative diseases. 
Rotenone was chosen as a complex I inhibitor for this study due to specific 
features. It is a naturally occurring pesticide (derived from plants) widely used on 
home-grown fruits and vegetables and also used as a fish toxin, so it is found in a 
variety of commercial garden and animal-care products. Rotenone is a potent and 
specific inhibitor of mitochondrial complex I, binding to subunit ND1 of complex I 
(Singer and Ramsay, 1994). It has features not found in two other common complex I 
inhibitors, 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) and amytal (Degli 
Esposti, 1998). Unlike MPTP, which is selective for dopaminergic neurons and 
depends on the dopamine transporters to gain access to the neurons, rotenone is 
extremely lipophilic and can easily penetrate biological membranes (Ernster et al., 
1963), while the highly charged 1-methyl-4-phenylpyridinium ion (MPP+, the main 
metabolite of MPTP) would have much more difficulty passing through. Rotenone has 
also been found to be more potent than MPP+ (Heikkila et al., 1986). Amytal is also a 
complex I inhibitor that had been used earlier (Ernster et al., 1955). However, a high 
concentration of amytal is required for maximal inhibition, and it inhibits enzymes 
other than complex I as well (Storey, 1980); therefore, it is neither a strong nor a 
specific inhibitor for complex I. Thus, rotenone may be a more appropriate model 
candidate than amytal as rotenone binds to the electron transfer system firmly and 
irreversibly (Ernster et al., 1963). In addition, rotenone may also offer a more widely 
applicable model of environmental toxin exposure than MPTP or amytal. 
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The neuronal toxicity of rotenone has been attributed to several aspects of 
defective cell metabolism. It blocks the oxidation of NADH to ubiquinone by binding 
to complex I, greatly reducing mitochondrial proton motive force necessary to 
generate the mitochondrial transmembrane potential, resulting in reduced production 
of ATP (Pastorino et al., 1995). Apoptosis has been induced by rotenone after 20 min 
in a liver cell line, and it was not reversed with the removal of rotenone (Isenberg and 
Klaunig, 2000). This indicates that mitochondrial dysfunction induced by acute 
rotenone administration may trigger a cascade of further damage, even in the absence 
of rotenone, eventually leading to cell death. 
The simplicity of our animal model may serve as a convenient way in vivo to 
study mitochondrial dysfunction in neurodegeneration. While animal models of 
Parkinson’s disease require chronic exposure to toxins over a period of weeks or 
months (Betarbet et al., 2000), the present model can be rapidly performed – it takes 
only about a day for robust damage to occur. Therefore, this animal model may 
provide an efficient and convenient way to screen new candidate treatments. 
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Chapter 4: Neurodegeneration Caused by Rotenone in the Mouse 
Retina: A Cellular Morphometric study 
 
4.1 ABSTRACT 
Rotenone is a widely used pesticide that inhibits complex I of the 
mitochondrial respiratory chain. Complex I dysfunction is linked to the degeneration 
of retinal ganglion cells in Leber’s hereditary optic neuropathy. The 
neurodegeneration of the retina was investigated in mice with intravitreal 
microinjection of rotenone in one eye and the vehicle dimethyl sulfoxide in the 
contralateral control eye, as a within-subject control. The retinal ganglion cell layer 
(GCL) of eyes injected with rotenone became significantly thinner than that of the 
control eyes after 24 h, but not as early as after 0.5 h. This reduction was observed 
with complex I histochemistry and with Nissl staining of cell bodies. After 24 h, 
retinal nerve fiber layer thickness was reduced by 89% and the number of GCL cells 
was reduced by 21% in rotenone-treated eyes. Cellular morphometric data (soma area, 
perimeter, and diameter) did not show overall differences, but there was a preferential 
reduction in the proportion of larger cells. Therefore, the reduction in GCL thickness 
after 24 h of rotenone microinjection could be accounted for by cell loss and nerve 
fiber shrinkage, but not by overall soma size change. Rotenone-induced degeneration 
of the ganglion cell layer could be used as a convenient way to evaluate mechanisms 




There is a compelling need to understand the mechanisms of 
neurodegeneration that may be caused or exacerbated by environmental toxins 
(Betarbet et al., 2000; Berndt et al., 2001; Sherer et al., 2003). Rotenone is a naturally 
occurring and widely used pesticide (Nagatsu, 2002), thus studies with rotenone may 
provide clues to an environmental role of pesticides in neurodegenerative diseases. 
Mitochondrial dysfunction is associated with neurodegenerative disorders such as 
Leber’s hereditary optic neuropathy, Parkinson’s disease, Huntington’s disease, and 
Alzheimer’s disease (Beal, 1998; Betarbet et al., 2000; Gonzalez-Lima and Cada, 
1998; Howell, 1998; Valla et al., 2001). A dysfunctional mitochondrial electron 
transport chain decreases ATP production and accelerates the generation of free 
radicals (Beal, 1998). Leber’s hereditary optic neuropathy (LHON) is regarded as a 
model disease for mitochondrial neurodegenerative diseases (Brown et al., 1992), and  
is the most common cause of blindness in otherwise healthy young men (Schapira, 
1998). It is also the most common disease associated with mutations of the 
mitochondrial DNA (mtDNA) (Manfredi and Beal, 2005). LHON is a maternally 
inherited disease which classically presents as acute or subacute onset with bilateral 
central vision loss associated with the degeneration of the retinal ganglion cell layer 
and the optic nerve (Howell, 1998).  
LHON is linked to mitochondrial complex I dysfunction (Brown et al., 1992). 
Complex I, nicotinamide adenine dinucleotide (NADH)-quinone oxidoreductase, is 
the first and the largest complex of the mitochondrial respiratory chain. It catalyzes the 
reduction of NADH to ubiquinone. Complex I is an integral membrane protein 
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complex composed of about 43 subunits, seven of which (ND1, ND2, ND3, ND4, 
ND4L, ND5 and ND6) are encoded by mitochondrial DNA (mtDNA) (Hatefi, 1985; 
Walker et al., 1992). About 90-95% of LHON cases are the result of one of three 
primary mitochondrial DNA (mtDNA) point mutations at nucleotide positions 
11778/ND4, 3460/ND1 and 14484/ND6 (Besch et al., 1999; Brown et al., 1992), all of 
which affect complex I (Beal, 1998). In addition, at least 14 different secondary 
mtDNA mutations have been found (Brown et al., 1992).  
We previously reported the first animal model for optic neuropathy resulting 
from mitochondrial dysfunction caused by rotenone toxicity (Zhang et al., 2002). 
Rotenone was used because it is a specific and irreversible inhibitor of mitochondrial 
complex I and it binds strongly to the ND1 subunit of complex I (Ernster et al., 1963; 
Lindahl and Oberg, 1961; Singer and Ramsay, 1990). Rotenone was intravitreally 
microinjected into one eye of each mouse, while the other eye was injected with only 
the vehicle, dimethyl sulfoxide (DMSO). The thickness of the retinal ganglion cell 
layer (GCL) of the rotenone-treated eyes showed significant reductions in the 1 h and 
24 h post-injection time groups, with the highest reduction of 41% at 24 h post-
injection, as compared to the DMSO-treated eyes. The inner plexiform layer (IPL) 
also showed a significant reduction in thickness in the 24 h group (Zhang et al., 2002). 
The objective of the present study was to determine whether the reduction in GCL 
thickness after 24 h of rotenone microinjection was caused by cell loss or shrinkage, as 
determined by morphometric analyses including soma area, diameter, and perimeter 
measurements. In addition, in the current study, we verified whether the rotenone 
effect could be detected using routine Nissl staining instead of enzyme histochemistry. 
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The results showed a significant cell loss in the GCL following rotenone treatment, 
which resembles the degeneration of retinal ganglion cells in Leber’s optic 
neuropathy. The results also revealed a significant reduction in the GCL thickness 
with Nissl staining. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Subjects 
Male CBA/J mice (N = 29, 25-44 g) (The Jackson Laboratory, Bar Harbor, 
ME) were used. Eighteen mice were studied after 24 h of intravitreal microinjection 
with one of four doses of rotenone (0.01, 0.3, 0.6, and 1.2 mM). The two lower doses 
showed no detectable effect, and all subsequent mice were therefore treated with the 
higher doses Two groups of mice given 1.2 mM microinjections of rotenone (0.2 
mg/kg) or vehicle were studied in two different post-injection time intervals before 
euthanasia (0.5 h and 24 h). Seven mice were treated identically for the 0.5 h post-
injection group. For the 24 h group, new tissue samples from 10 subjects included in a 
previous study (Zhang et al., 2002) were used. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee (IACUE) of the 
University of Texas at Austin, and conformed to NIH Guidelines. 
 
4.3.2 Intravitreal microinjection procedures  
The mice were anesthetized by an intraperitoneal injection of a mixture of 
ketamine hydrochloride (45 mg/kg), xylazine hydrochloride (9 mg/kg), and 
acepromazine (1.5 mg/kg). One eye of each mouse was intravitreally microinjected 
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with 0.5 µl rotenone in DMSO. Intravitreal microinjections were performed by an 
experienced ophthalmologist using a stereomicroscope and microinjection system. A 
small sclerotomy was performed using a fine needle (30 gauge) inserted just behind 
the limbus of the cornea in the superior and temporal quadrant of the eye to give 
access to the vitreous body. The microinjection was done immediately underneath the 
corneoscleral junction with a blunt needle to avoid the lens and the retina. 
Microinjections were administered via 30-G blunt-ended dental injection needles 
(Monoject®, Sherwood Medical Company, Norfolk, NE) connected by polyethylene 
tubing to 10-µl Hamilton microsyringes (Hamilton Company, Reno, NV). The 
injections were delivered over 2 min using a CMA 100 microinjection pump (CMA 
microdialysis AB, North Chelmsford, MA), and the injection needles were left in 
place for an additional 40 s to allow for diffusion away from the needle tip and to 
avoid any efflux of fluid through the injection site (Salinas et al., 1997). The edges of 
the injection point were gripped with forceps while the microsyringe was slowly 
withdrawn. Then, a small amount of n-butyl cyanoacrylate monomer (Nexaband liquid 
tissue adhesive, Veterinary Products Laboratories, Phoenix) was applied on the 
surface of the injection point to form a sealed thin layer.  
The estimated local concentration of rotenone in the eye was either 0.6 mM or 
1.2 mM based on a measured eyeball volume averaging 13 µl in the mice. The other 
eye received the same volume and rate of the vehicle DMSO as a within-subject 
control. Following decapitation, the eyeballs and brains were rapidly removed, frozen 
in isopentane, and sectioned coronally at 20 µm in a cryostat (Reichert-Jung) at –18oC. 
Four adjacent series were created for histochemical analysis.  
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4.3.3 Retinal laminar thickness measurement in sections stained for complex I  
Mitochondrial complex I staining was used because rotenone is a selective 
complex I inhibitor. Complex I is sensitive to the effect of rotenone, and the 
histochemical reaction used can be partially inhibited by adding rotenone (Jung et al., 
2002). Also, the neuropil surrounding the cell bodies in the GCL, including the optic 
nerve fibers at the inner surface of the GCL, is visible in complex I but not in cresyl 
violet stained tissues. Therefore, complex I staining was suitable for the retinal 
thickness measurement reflecting both cell bodies and neuropil, whereas cresyl violet 
staining delineated only cell bodies. 
To determine whether the rotenone treatment reduces GCL thickness after a 
half hour of treatment, one series of sections from the 0.5 h group were stained for 
complex I activity following a well-documented method using tetrazolium salts (Barry 
et al., 1993; Sims et al., 1974). Tetrazolium salts are colorless or yellow and water-
soluble; they can be reduced metabolically to the highly colored water-insoluble 
microcrystalline deposits called formazans by accepting hydrogen released from the 
substrate (NADH) through enzyme action which is, in this case, complex I. Slides 
with fresh-frozen 20 µm sections were put into three baths, 5 min each, of 0.1 M 
sodium phosphate buffer solution (PBS) with 10% (w/v) sucrose. The temperatures of 
the three baths were graded from about 4oC to room temperature to bring the slides 
gradually to room temperature as a transition to the incubation temperature of 37oC. 
After rinsing in 0.1 M PBS, slides were incubated at 37oC in the dark for 15-20 min 
with agitation in phosphate buffer containing NADH (Sigma, 1 mg/ml), nitroblue 
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tetrazolium (Sigma, 1.33 mg/ml), and sodium azide (Sigma, 0.065 mg/ml). Sodium 
azide was used to inhibit cytochrome oxidase (complex IV) (Gonzalez-Lima and 
Cada, 1998). 
Using a computerized microimaging system including an Olympus BX40 
microscope with a 40x objective (Olympus America; Lake Success, NY), a CCD 
camera (Javelin Electronics; Torrance, CA), a Targa M8 image capture board and 
JAVA imaging software (Jandel Scientific; Corte Madera, CA), thickness was 
measured in the GCL, the IPL, and the whole retina, from eye sections stained for 
complex I activity. To avoid the effect of retinal thickness by location, data were taken 
from the center of the retina at a distance of approximately twice the diameter of the 
optic disc away from the center of the optic disc. 
 
4.3.4 GCL thickness in cresyl violet stained sections and estimate of retinal nerve 
fiber layer (RNFL) thickness in the 24 h post-injection group 
To determine if the reduction in GCL thickness by rotenone is caused by loss 
of cells or stain in the GCL, a series of sections was Nissl-stained with cresyl violet 
and used for GCL thickness, cell count, and morphometric analysis of cell bodies. The 
cresyl violet staining procedure consisted of dehydration of the fresh frozen tissue 
sections followed by staining (0.1% cresyl violet, 6-10 min) and rehydration in a series 
of graded ethanols (70-100%). Slides were then cleared in xylene and coverslipped 
with Permount. The same microscopic image-processing system and sampling 
procedure described for thickness measurement was used.  
The RNFL at the inner surface of the GCL is mostly composed of axons of 
retinal ganglion cells. In the cresyl violet stained tissue the cell bodies are clearly 
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visible but the axons are not. To estimate the size of the thinning effect of rotenone in 
RNFL, GCL thickness was measured in cresyl violet-stained sections that do not show 
the retinal nerve fibers and only reveal the cell bodies in the GCL. Then the data were 
compared to the GCL thickness data taken from the complex I stained series of 
sections in which the RNFL contributed to the GCL thickness. A comparison of these 
two stains provided a reliable estimate of the RNFL thickness. A direct measurement 
using only one stain was unreliable because the RNFL of the treated eyes became too 
thin to be measured accurately. 
 
4.3.5 Cell counts and morphometric analysis of somata of retinal GCL in cresyl 
violet-stained sections  
Readings were taken from approximately the same length and location of the 
GCL in the retinal cross-sections in all eyes, and the sections with the largest diameter 
of the eye were chosen to control the variation of retinal thickness among sections. 
The profile cell counting was chosen because the number of the soma profiles in the 
GCL was counted only for the purpose of comparing rotenone-treated and non-treated 
eyes within each mouse. In addition, the sections examined were from every fourth 
consecutive 20 µm-thick section. Thus individual ganglion cells were unlikely to be 
counted more than once because soma diameters were smaller than 20 µm. In the 
mouse retina, most of the cells in GCL are retinal ganglion cells concentrated in the 
center. Other cells in GCL are small glial cells and displaced amacrine cells. The 
displaced amacrine cells are concentrated in the periphery of the mouse retina rather 
than the center (Drager and Olsen, 1981). The GCL cell counts were made at the 
center of the retina. Retinal ganglion cells were not distinguished from other cells in 
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the GCL because in the central retina, where the readings were taken, the ganglion 
cells are not displaced as in the periphery of the retina (Drager and Olsen, 1981). 
To determine whether the reduction in GCL thickness by rotenone is caused by 
the shrinkage of the cells in the GCL, soma area, diameter (average of the long and 
short axis of each soma profile), and perimeter were measured from each soma profile 
in the GCL with the same image analysis system used for thickness measurement. 
About the same length of the GCL in the retinal cross sections from each eye was used 
for data collection. 
 
4.3.6 Statistics 
To analyze the effect of rotenone on soma size, we calculated the mean, mean 
+1 standard deviation (SD), and mean – 1 SD from the data of all the cells from both 
the DMSO control group and the rotenone treated group. The values were used for 
cut-off points to divide the total somata into four size categories for each 
morphometric measurement. This was done for both rotenone and DMSO treated 
groups.  
Two-tailed t-tests at p < 0.05 were used with paired samples from both eyes in 
each subject, to test the significance of differences between the rotenone-treated eye of 
each subject and its vehicle DMSO-treated control eye. The “n” equals number of 
mice with pairs of treated and control eyes. 
To compare the cell numbers in the largest cell size category in the GCL of 
rotenone-treated vs. DMSO-treated control eyes, a Chi-square test was used to analyze 




The mice receiving rotenone and DMSO eye microinjections did not show 
evidence of malaise or behavioral alterations. The pupillary light reflex was tested 
immediately before decapitation and it was present in both eyes for all the subjects. No 
differences in histochemical staining could be seen in sections taken from the brains of 
these mice. The effects of the eye microinjection appeared limited to the retina. 
 
4.4.1 Decreased somata and axons of GCL cells in the 24 h post-injection group 
The GCL reduction can be detected by microscopic inspection after 24 h post-
injection (Figure 4.1A and C). Using the cresyl violet staining technique, in which 
only somata can be observed, a significant 18% reduction of GCL thickness was 
measured (n = 9, p = 0.038). However, as early as 0.5 h post-injection, the results 
revealed no significant difference in the thickness of GCL (DMSO 21.43 ± 1.43 µm, 
rotenone 20.47 ± 1.19 µm) and the whole retina (DMSO 87.80 ± 5.57 µm, rotenone 
95.78 ± 6.33 µm) in rotenone treated eyes as compared to that of the DMSO treated 
eyes.  
Figure 4.1 Cross-section of the mouse retina with cresyl violet staining (A, C) and 
complex I staining (B, D) in rotenone treated (A, B) and DMSO treated 
control (C, D) of 24 h post-injection group. The thickness of the ganglion 
cell layer (GCL) and the retinal nerve fiber layer (RNFL) is clearly 
reduced in the rotenone treated eye as compared to the control eye. Color 
is needed to distinguish RNFL (blue) from the immediately adjacent 
GCL (red) in B and D. Digitized images set to 560x magnification. The 





The RNFL reduction can also be observed by microscopic inspection (Figure 
4.1B and D). The thicknesses of the GCL including RNFL from complex I staining are 
23.82 ± 1.97 µm and 13.87 ± 1.16 µm for the DMSO and the rotenone treated groups 
respectively. The thicknesses of the GCL excluding the RNFL can be obtained from 
cresyl violet-stained sections, and they are 16.33 ± 1.52 µm and 13.07 ± 1.05 µm for 
the DMSO and the rotenone treated group, respectively. The combined information on 
GCL thickness reduction provided by the two different staining methods can provide 
an estimate of thickness reduction in the RNFL alone. The difference in GCL 
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thicknesses obtained from the two different staining methods are 7.49 ± 2.12 µm and 
0.79 ± 1.16 µm for the DMSO and the rotenone treated groups, respectively. There 
was a large and significant reduction of 89% in RNFL thickness in the rotenone group 
(n = 9, p = 0.009).  
The 1.2 mM rotenone microinjection was clearly effective in reducing retinal 
thickness as compared to 0.6 mM (Figure 4.2). Therefore, the 1.2 mM rotenone 
microinjection was chosen for the comparison of the 0.5 h and 24 h post-injection 
interval groups in this and our previous studies (Zhang et al., 2002). 
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Figure 4.2 Percent reduction in thickness of the ganglion cell layer as a function of 
rotenone concentration in the eye. 
 
Rotenone concentration in the eye
























The effect of post-injection interval on retinal thickness is shown in Figure 4.3. 
Significant overall reductions in GCL (including RNFL = 41%, n = 10, p < 0.001) and 
IPL (13%, n = 10, p < 0.05) were found after 24 h post-injection, but no significant 
change was found in the thickness of the rest of the retina (Figure 4.3A). There were 
no differences in the 0.5 h post-injection group and the non-injected group (Figure 
4.3B and C). 
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4.4.2 Increased thickness in the inner plexiform layer (IPL) of 0.5 h post-injection 
group  
Thickness of the IPL in the rotenone treated eyes was significantly increased 
compared to that in the control eyes at 0.5 h post-injection time (n = 7, p = 0.04) 
(Figure 4.3B). The percent increase of the rotenone treated IPL is 11% as calculated 
from paired data of treated and control eyes. For testing the effect of rotenone on 
retinal layers other than the GCL and IPL, the thickness of the GCL and IPL was 
subtracted from that of the whole retina. No significant statistical differences were 
found in the rest of the retina. 
 
 
Figure 4.3 Thickness of the ganglion cell layer, inner-plexiform layer and rest of the 
retina in complex I stained eyes with 24 h (A) and 0.5 h (B) post-
injection time, and with no injection (C). Asterisks indicate statistically 


























































4.4.3 Cell counts in the GCL of 0.5 h and 24 h post-injection groups 
In the 0.5 h post-injection time group, there was a non-significant reduction in 
the number of the cells in the GCL between rotenone and DMSO treated eyes (Figure 
4.4). This is consistent with the result that the GCL thickness in the 0.5 h group did 
not show a significant difference between the rotenone and DMSO treated eyes.  
However, in the 24 h group, the number of the cells in GCL of rotenone treated 
eyes was significantly reduced (21% percent reduction) from that of the vehicle 
treated eyes (n = 8, p = 0.02), (Figure 4.4).  
 
Figure 4.4 Percent of GCL cells in rotenone treated eyes as compared to DMSO 




































4.4.4 Soma morphometry and frequency distribution in cresyl violet-stained 
sections  
No significant differences were found between DMSO and rotenone-treated 
eyes in measurements of soma area, diameter, or perimeter of the GCL cells in the 0.5- 
or 24 h groups. The soma area, diameter and perimeter were reduced by only about 
2.5% in rotenone treated eyes of the 24 h group (Figure 4.5). This suggested that for 
the cells observed in the GCL, thinning of the GCL by rotenone injection could not be 
accounted for by overall cell shrinkage.  
 
 
Figure 4.5 Soma morphometry in GCL of rotenone treated and control eyes in the 
























































The morphometric analysis also revealed that the cell loss in the 24 h group 
was not uniform among cells of different sizes. There was a reduction in the 
proportion of larger cells in the 24 h post-injection group. In the largest cell category 
(soma diameter > 10 m), rotenone-treated GCL had fewer cells compared to DMSO-
treated control eyes in the 24 h group (Figure 4.6). A Chi-square test showed this 
preferential loss of larger cells (larger than mean + 1 SD) in the rotenone-treated group 
in the 24 h group was significant and was consistent through all measures of area (n = 
108, p < 0.01), diameter (n = 140, p < 0.0001), and perimeter (n = 227, p < 0.001) 
(Figure 4.7). However, this was the opposite pattern found in the 0.5 h group (Figure 
4.7), but this trend did not reach the statistical significance (Chi-square test)  
 
 
Figure 4.6 Frequency of cells in the GCL as a function of soma diameter in 24 h 
group. Cell counts were taken from the center of the retina about twice 
the diameter of the optic disc away from the center of the optic nerve for 
a GCL length about 155 µm. *P < 0.0001, when the cell number in the 
rotenone eyes was compared to that of the control eyes (the dashed line) 



























Figure 4.7 Percentage of GCL cells by soma area (A and B), diameter (C and D), 
and perimeter (E and F) in rotenone treated as compared to the DMSO 
treated eyes in 0.5 h (A, C, and E) and 24 h (B, D, and F) groups. Cells 
were divided into four size categories using the mean – 1 standard 
deviation, mean, and mean + 1 standard deviation of all the cells from 
both rotenone and DMSO treated eyes. *P < 0.01, when the cell number 
in the rotenone eyes was compared to that of the control eyes (the dashed 
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The observed cell loss is consistent with GCL thickness reduction in rotenone 
treated eyes of the 24 h post-injection group (Zhang et al., 2002) and is also in line 
with the ganglion cell loss of LHON patients (Howell, 1998). A significant 18% 
reduction in GCL thickness was observed using the cresyl violet technique, in which 
only cell bodies are stained, suggesting that the effect of 1.2 mM rotenone on the GCL 
is not simply an artifact observed with complex I histochemical staining. This thinning 
of GCL by rotenone microinjection in the 24 h group (Zhang et al., 2002) could be 
accounted for by the observed 21% cell loss. The larger reduction (41%) of GCL 
thickness seen with complex I staining, which reflects ganglion cell bodies (GCL) and 
their axons (RNFL), could be accounted for by the additional 89% thinning of the 
RNFL.  
However, the observed GCL decreases at 24 h post-injection do not appear to 
be caused by soma shrinkage. In addition, there was no significant change in the 
thickness or the cell number of GCL as early as 0.5 h after intravitreal treatment with 
1.2 mM rotenone. We have previously observed that GCL thickness was significantly 
reduced by 28% one hour after a similar microinjection of rotenone (Zhang et al., 
2002). This suggests that GCL thickness starts to decrease between 0.5 and one hour 
after 1.2 mM rotenone microinjection.  
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The method for quantifying the RNFL thickness reduction observed (Figure 
4.1) was indirect because of the resulting negligible size of this layer in the rotenone-
treated eyes. While this approach was not ideal, the pronounced thinning of the RNFL 
observed in the current study provided clear evidence that this layer was very 
susceptible to the inhibition of complex I activity by rotenone. The RNFL contains 
unmyelinated axons of the ganglion cells, and stained darkly for complex I, as 
opposed to the light staining of the optic nerve segment caudal to the lamina cribosa (a 
connective tissue consisting of holes through which axons cross into the myelinated 
optic nerve). The same pattern of staining has been reported in mitochondrial complex 
II and complex IV activity in monkeys and humans (Andrews et al., 1999; Kageyama 
and Wong-Riley, 1984). Myelinated segments of optic axons are energy and 
temporally efficient because ATPases on these fibers cluster only within the nodes of 
Ranvier and depolarization occurs in a “saltatory” fashion along successive nodes of 
Ranvier (Waxman and Ritchie, 1993). On the other hand, the unmyelinated segment of 
optic nerve axons (the prelaminar portion of the optic nerve, mostly RNFL) requires a 
much greater flow of current resulting in slow conduction velocity and high energy 
demand, because these axons are associated with a more uniform membrane 
distribution of ATPases (Waxman and Ritchie, 1993). Therefore, the unmyelinated 
RNFL has a higher demand for oxidative phosphorylation, making it a possible 
“choke-point” in LHON and other optic neuropathies (Carelli et al., 2002; Howell, 
1998), and likewise this layer is more vulnerable to insult by rotenone. 
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The IPL contains ganglion cell dendrites and the processes of bipolar and 
amacrine cells. This layer stained darkly for complex I in our study. Kageyama and 
Wong-Riley (1984) also reported that the ganglion cell dendrites stained moderate to 
darkly and contributed to the overall intensity of cytochrome oxidase staining in the 
IPL. The above observations indicated a contribution of highly active mitochondrial 
enzymatic activity of ganglion cell dendrites in the IPL, which may be associated with 
the rich synaptic interactions in this layer. Our results of the thickness and cell number 
measurements from the 0.5 h group suggest that cell loss is not significantly involved 
during the early stage of the impairment of mitochondrial function caused by rotenone 
treatment. Rather than cell loss, there was evidence of enlargement of the retinal 
ganglion cell dendrites by 0.5 h, which may indicate initial swelling.  
Rizzo (1995) and Sadun et. al. (2000) have reported that the papillomacular 
bundle formed by all macular area axons that are located centrally is selectively 
involved in a range of genetic or acquired optic neuropathies in humans. Sadun et. al. 
(2000) reported that smaller axons, presumably belonging to the P- (parvo-) ganglion 
cell pathway, were differentially affected in LHON. However, that conclusion might 
need further investigation because it was based on only two female cases with two 
normal males used as controls. Further, the spectra of the optic nerve fiber size 
showed an increased number of large axons, and the possibility of smaller axons 
swelling in response to the insult of the disease could not be excluded. Even though 
mouse retina does not contain a macula, its small and medium-sized retinal ganglion 
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cells distribute densely in the central retina, and large cells are mostly in the peripheral 
regions of the retina, as in primates and other rodents (Drager and Olsen, 1981; 
Kageyama and Wong-Riley, 1984). The somata that were measured in our studies 
presumably belong to a population of small-medium sized ganglion cells because data 
were taken from the center of the retina. However, our data showed that the larger 
ganglion cells among this population were the most vulnerable to rotenone. In the 24 h 
group, cells with larger somata were more reduced in numbers than smaller ones 
(Figure 4.6 and 4.7). The preferential loss of the larger cells may be caused by cell 
death and/or cell shrinkage, and may be associated with more mitochondria in the cell. 
It has been shown that in Alzheimer’s disease, the large ganglion cells or M- (Magno-) 
cells were preferentially affected (Sadun and Bassi, 1990). It has also been reported 
that larger ganglion cells are more sensitive to intraocular injection of NMDA (Dreyer 
et al., 1994), more vulnerable to glaucomatous damage (Quigley et al., 1988), which 
are associated with ischemia and excitotoxicity (Osborne et al., 1999). The preferential 
loss of larger cells in our study may indicate that the mechanisms of rotenone toxicity 
may be similar to the effects of ischemia and excitotoxicity in these cells. 
The 21% cell body loss in the GCL of rotenone-treated eyes is consistent with 
the neurodegeneration of the GCL in LHON. The neuronal toxicity of rotenone has 
been attributed to several aspects of defective cell metabolism. Rotenone blocks the 
oxidation of NADH to ubiquinone by binding to complex I, greatly reducing the 
mitochondrial proton motive force necessary to generate the mitochondrial 
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transmembrane potential, resulting in reduced production of ATP and increased 
production of reactive oxygen species. In vitro studies have shown that complex I 
inhibitors induce apoptosis. For example, apoptosis has been induced by rotenone after 
12-18 h of administration (Wolvetang et al., 1994). Mitochondrial dysfunction triggers 
a cascade of apoptosis that continues after removal of rotenone, irreversibly leading to 
cell death (Barrientos and Moraes, 1999; Isenberg and Klaunig, 2000). The early steps 
of this pathway may involve mitochondrial swelling and release of cytochrome c, 
which triggers apoptosis (Howell, 1998); this was also suggested from our 
measurements of increased thickness and cell number in the 0.5 h post-injection time 
group (Figures 4.3B and 4.4).  
The etiology of LHON is complex. For example, the penetrance of LHON is 
not complete. This means that not all individuals harboring a primary mutation express 
the disease at the phenotypic level (Howell, 1998). The primary mtDNA mutation is 
not sufficient for the manifestation of the optic neuropathy. The disparity between the 
phenotypic expression and the genotype suggests that the genetic factor is not the sole 
determinant; the etiology of mitochondrial neuropathies may not be simply one of 
genetic defects but may be exacerbated by or caused by environmental toxic agents 
inhibiting mitochondrial respiration (Berndt et al., 2001). It has been reported that 
exposure to tobacco, alcohol, and a variety of less common toxins including pesticides 
(Carelli et al., 2002) increased penetrance in LHON pedigrees. In fact, the clinical 
manifestation of toxic and nutritional optic neuropathies remarkably resemble that of 
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LHON (Carelli et al., 2002). Therefore, environmental factors are needed to express 
the neuropathy. This idea is also supported by toxicological studies of Parkinson’s 
disease, which indicate links to rotenone, a commonly used pesticide and a 
mitochondrial complex I inhibitor (Betarbet et al., 2000). More attention should be 
brought to the contribution of exposure to environmental toxins, including pesticides, 
and the incidence of mitochondrial neurodegenerative diseases. 
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Chapter 5: Methylene Blue Prevents Neurodegeneration Induced by 
Rotenone in Mouse Retinal Ganglion Cell Layer 
 
5.1 ABSTRACT 
An experimental optic neuropathy model was used to test the hypothesis that 
methylene blue, as an antioxidant, may protect the retinal ganglion cell layer from 
neurodegeneration caused by rotenone. Rotenone is a widely used pesticide that 
inhibits complex I, the first enzyme of the mitochondrial respiratory chain. Complex I 
dysfunction is linked to the degeneration of retinal ganglion cells in Leber’s optic 
neuropathy. Methylene blue is a reduction–oxidation agent that can act as a powerful 
antioxidant, preventing formation of mitochondrial oxygen free radicals. The 
neurodegeneration of the retina was studied in mice with intravitreal microinjection of 
rotenone alone, or in combination with increasing doses of methylene blue, in one eye, 
and the vehicle in the contralateral control eye. Rotenone induced neurodegeneration 
in the retinal ganglion cell layer 24 h after injection, as indicated by significant 
reductions in both the thickness and cell numbers of the retinal ganglion cell layer of 
eyes microinjected with rotenone as compared to the control eyes. This 
neurodegeneration was completely prevented by the injection of methylene blue along 
with rotenone. The effect of rotenone and rotenone plus methylene blue was 
investigated using two histological stains, complex I and Nissl, and two 
measurements, morphometric layer thickness and non-biased stereological cell counts. 
The protective effect of methylene blue appeared to be related to its antioxidant action 
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because cytochrome oxidase activity was similarly activated in rotenone and rotenone 
plus methylene blue groups. It was concluded that rotenone-induced degeneration in 
the ganglion cell layer can be prevented by intravitreal injection of methylene blue. 
The findings suggest that methylene blue may be a promising therapeutic agent in 
optic neuropathy and perhaps other neurodegenerative diseases caused by 
mitochondrial dysfunction.  
 
5.2 INTRODUCTION 
Dysfunction of the mitochondrial electron transport chain has been implicated 
in the pathogenesis of neurodegenerative disorders such as Leber’s optic neuropathy, 
Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease (Beal, 1998; 
Betarbet et al., 2000; Gonzalez-Lima and Cada, 1998; Howell, 1998; Valla et al., 
2002). Leber’s optic neuropathy, which classically manifests as bilateral central vision 
loss associated with degeneration of the retinal ganglion cell layer and the optic nerve 
(Howell, 1998), is linked to mitochondrial complex I dysfunction (Brown et al., 1992). 
Complex I, also known as nicotinamide adenine dinucleotide (NADH)-quinone 
oxidoreductase, is the first and the largest complex of the mitochondrial respiratory 
chain. It catalyzes the reduction of NADH to ubiquinone (coenzyme Q) (Schapira, 
1998). Complex I is more susceptible to oxidative inactivation following exposure to 
free radicals than other mitochondrial enzymatic complexes such as cytochrome c 
oxidase (Zhang et al., 1990). 
Rotenone is a naturally occurring and widely used pesticide that inhibits the 
ability of mitochondrial complex I to transfer electrons to coenzyme Q (Degli Esposti, 
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1998; Lindahl and Oberg, 1961; Singer and Ramsay, 1994). Thus, studies with 
rotenone may provide clues to the environmental role of pesticides in optic neuropathy 
and neurodegenerative diseases linked to mitochondrial dysfunction (Betarbet et al., 
2000). A dysfunctional mitochondrial electron transport chain decreases ATP 
production and accelerates the generation of free radicals leading to cell death 
(Gonzalez-Lima et al., 1998; Beal, 1998) 
Methylene blue (MB) is an oxidation-reduction (redox) agent previously used 
safely in humans as an antidote for certain metabolic poisons (Bradberry, 2003; 
Clifton and Leikin, 2003) as well as a neuroprotective agent for treatment of drug-
induced encephalopathy, dementia and manic-depressive psychosis (Naylor et al., 
1986; Kupfer et al., 1996; Wainwright and Crossley, 2002). MB can prevent the 
formation of superoxide (Kelner et al., 1988; Salaris et al., 1991) and nitric oxide 
(Mayer et al., 1993) in mitochondria. An early study by Lindahl and Oberg (1961) 
suggested that MB may be effective in reversing the effects of rotenone. They 
demonstrated that exposure of intact and excised gill filaments to rotenone induced a 
decreased oxygen consumption, and addition of MB reduced the inhibition of oxygen 
uptake caused by rotenone after excision (Lindahl and Oberg, 1961). Therefore, MB 
may act therapeutically as an antioxidant in experimental optic neuropathy and 
perhaps other forms of neurodegenerative diseases characterized by inhibition of 
mitochondrial complex I. 
We previously investigated the neurodegenerative effects of rotenone on the 
retina of mice injected with rotenone in one eye and the vehicle dimethylsulfoxide 
(DMSO) in the contralateral eye as a within-subject control. We found that the retinal 
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ganglion cell layer of eyes injected with rotenone became significantly thinner than 
that of the control eyes after 24 h (Zhang et al., 2002). The objective of the present 
study was to test the hypothesis that the antioxidant MB may protect the retina from 
the neurodegeneration caused by rotenone in this experimental optic neuropathy 
model (Zhang et al., 2002).  
 
5.3 MATERIALS AND METHODS 
5.3.1 Subjects 
Male CBA/J mice (average weight 29 g) (Jackson Laboratory, Bar Harbor, 
ME) were used. All experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the University of Texas at Austin. 
 
5.3.2 Surgery  
The mice were anesthetized by an intraperitoneal injection of a mixture of 
ketamine hydrochloride (45 mg/kg), xylazine hydrochloride (9 mg/kg), and 
acepromazine (1.5 mg/kg). Intravitreal microinjections were performed by an 
experienced ophthalmologist (X. Zhang) using a stereomicroscope and microinjection 
system. A small sclerotomy was performed using a fine needle (30-G) inserted just 
behind the limbus of the cornea in the superior and temporal quadrant of the eye to 
give access to the vitreous body. The microinjection was done immediately 
underneath the corneoscleral junction with a blunt needle to avoid the lens and the 
retina. The 30-G blunt-ended dental injection needles (Monoject®, Sherwood Medical 
Company, Norfolk, NE) were connected by polyethylene tubing to 10-µl Hamilton 
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microsyringes (Hamilton Company, Reno, NV). The injections were delivered over 2 
min using a microinjection pump (CMA microdialysis AB, North Chelmsford, MA), 
and the injection needles were left in place for an additional 40 sec to allow for 
diffusion away from the needle tip and to avoid any efflux of fluid through the 
injection site. The edges of the injection point were gripped with forceps while the 
microsyringe was slowly withdrawn. Then a small amount of n-butyl cyanoacrylate 
monomer (Nexaband liquid tissue adhesive, Veterinary Products Laboratories, 
Phoenix) was applied on the surface of the sclera at the injection point to form a sealed 
thin layer.  
 
5.3.3 Drug treatments 
Methylene blue was purchased from Faulding Pharmaceutical Co., Paramus, 
NJ. All other chemicals were purchased from Sigma-Aldrich, St. Louis, MO. One eye 
of each mouse was intravitreally microinjected with 0.5 µl of DMSO, rotenone, or 
with MB/rotenone. The 0.2 mg/kg rotenone dose we used was based on our previous 
study, in which we compared rotenone doses of 0.065, 0.1 and 0.2 mg/kg, and found 
that 0.2 mg/kg produced thickness reduction of the ganglion cell layer and the inner 
plexiform layer without nonspecific reduction of the rest of the retina (Zhang et al., 
2002). The rotenone dose we used is low compared to doses used in another model of 
rotenone-induced neurodegeneration in the nigrostriatal pathway. Sherer et al. (Sherer 
et al., 2003) used rotenone doses of 2-3 mg/kg/day given subcutaneously for 28 or 56 
days. The single intravitreal 0.2 mg/kg dose we used is unlikely to have nonspecific 
 103 
systemic effects because it is ten times or more lower than the doses of rotenone used 
chronically by others to induce nigrostriatal neurodegeneration. 
To the best of our knowledge, no reactions between rotenone and methylene 
blue have been reported based on a literature search in Chemical Abstracts Service and 
Medline database from 1907-2004. To rule out the possibility that rotenone and 
methylene blue might react, we mixed 100 µl methylene blue (0.406 mg/ml) with 100 
µl rotenone (6.15 mg/ml), at half the concentrations used in the experiments, with 
acetonitrile and ethanol as the solvent. The mixture was allowed to sit at room 
temperature, and 10 µL of the mixture was taken out and injected in HPLC at 0, 10, 
20, 30, and 60 min, respectively. The results showed clearly that no reactions occurred 
(spectra not shown). Therefore, tests using HPLC further ruled out the possibility that 
they might react. 
The LD50 of MB for mice is 77 mg/kg i.v. (United States National Toxicology 
Program, 1990). The non-toxic MB doses chosen were approximately 1,000 times, 
10,000 times and 100,000 times smaller than this LD50 dose. Hence, in the MB dose-
response study, the three doses of MB added into rotenone were 0.07 mg/kg, 0.007 
mg/kg, and 0.0007 mg/kg. The most effective neuroprotective MB dose of 0.07 mg/kg 
was used for the Nissl study to compare cell counts after rotenone alone or rotenone 
plus MB. The control eye received the same volume and rate of the vehicle DMSO as 
a within-subject control. Mice were decapitated 24 h after drug treatment. The 
eyeballs were rapidly removed, frozen in isopentane, and sectioned antero-posteriorly 
at 30 µm in a cryostat (Reichert-Jung, Germany) at –18oC. Three adjacent series were 
created for histochemical analysis. 
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5.3.4 Histology 
5.3.4.1 Complex I staining 
To determine if the ganglion cell layer (GCL) thickness changed after the 
addition of MB to the rotenone, a series of sections was stained for complex I activity 
following a well-established histochemistry procedure using tetrazolium salts (Jung et 
al., 2002). By accepting hydrogen released from the substrate NADH through complex 
I enzymatic action, tetrazolium salts are reduced to highly colored water-insoluble 
microcrystalline deposits (see Chapter 2 for details). Briefly, fresh-frozen sections 
were incubated at 37oC for 15-20 min with agitation in phosphate buffer containing 
NADH (Sigma, 1 mg/ml), nitroblue tetrazolium (Sigma, 1.33 mg/ml), and sodium 
azide (Sigma, 0.065 mg/ml) (Zhang et al., 2002). 
 
5.3.4.2 Nissl staining 
To confirm that the GCL thickness and cell number changed after the addition 
of MB to rotenone, and to verify that the thickness change was not simply due to the 
loss of the stain in complex I staining, another series of sections was stained with 
cresyl violet and used for thickness and cell count measures in the GCL. The cresyl 
violet staining procedure consisted of dehydration of the fresh-frozen tissue sections 
followed by staining (0.1% cresyl violet, 6-10 min) and dehydration in a series of 




5.3.4.3 Cytochrome oxidase (complex IV) staining 
Cytochrome oxidase is the third and final proton-pumping protein of the 
electron transport chain in mitochondria. It plays a vital role in oxidative 
phosphorylation, in which electrons are accepted by oxygen to produce water, and the 
proton gradient is used by ATP synthase to produce ATP. Cytochrome oxidase 
activity is closely correlated to neuronal activity and oxygen consumption, and it is a 
reliable marker for long-term neuronal activity (Gonzalez-Lima and Cada, 1998; 
Nobrega et al., 1993; Wong-Riley, 1989). 
Quantitative cytochrome oxidase histochemistry measurements were taken to 
determine the effect of rotenone and MB/rotenone on neuronal activity and oxygen 
consumption in the retina. Since the ganglion cell layer is difficult to define on the 
retina with cytochrome oxidase staining, samples were taken in the inner plexiform 
layer (IPL) and the optic nerve, which contain mostly the dendrites of ganglion cells, 
and the neurites of bipolar cells and amacrine cells. Using previously described 
procedures (Gonzalez-Lima and Cada, 1994; Gonzalez-Lima and Jones, 1994; 
Gonzalez-Lima et al., 1997; Gonzalez-Lima and Cada, 1998), a series of retinal fresh-
frozen sections was treated in 10% sucrose phosphate buffer containing 0.5% 
glutaraldehyde for five min. After three changes at five min each of 10% phosphate 
buffer, the slides were preincubated for 10 min in Tris buffer (275 mg/l cobalt 
chloride, 10% sucrose, and 0.5% DMSO). After another rinse in phosphate buffer, the 
slides were then incubated at 37oC for 90 min in 700 ml of an oxygen saturated 
solution containing 350 mg of diaminobenzidine tetrahydrochloride, 52.5 mg of 
cytochrome c, 35 g of sucrose, 14 mg of catalase, and 1.75 ml of DMSO in phosphate 
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buffer. The reaction was stopped and the tissue was fixed by immersing the slides in 
10% glutaraldehyde for 30 min, before dehydrating gradually in ethanols, clearing in 
xylene, and coverslipping with Permount. 
 
5.3.5 Measurements 
Thickness was measured in the GCL using a computerized micro-imaging 
system consisting of an Olympus BX40 microscope with a 40x objective (Olympus 
America; Lake Success, NY), a CCD camera (Javelin Electronics; Torrance, CA), a 
Targa M8 image capture board and JAVA imaging software (Jandel Scientific; Corte 
Madera, CA). The Nissl stain revealed only somata of the GCL while the complex I 
stain also labeled the GCL neuropil. Therefore the nerve fiber layer on the inner side 
of the GCL was included in the complex I GCL thickness measurement. 
Cell count in the GCL was measured with a 60x oil immersion objective at a 
final magnification of 1200, using the Neurolucida system (version 5 
MicroBrightField, Williston, VT, USA). An unbiased optical dissector stereological 
method was applied; that is, any cells present on the top of the section were not 
counted. Because there was a decreased thickness of GCL in rotenone treated eyes 
(Zhang et al., 2002), cell number was counted in 3-dimensions as number of cells per 
length of the cross section of GCL and per thickness of the section on the slide, which 
is equal to cell counts per unit area of the retinal surface. 
Quantitative cytochrome oxidase histochemistry measurements were taken 
using the same imaging setup as for the Nissl staining study (see above) to evaluate 
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the effects of rotenone and MB/rotenone on energy demand in the dendrites (IPL) and 
axons (optic nerve) of the ganglion cells. 
To avoid the effect of retinal thickness by location, data were taken from the 
center of the retina at a distance of approximately twice the diameter of the optic disc 
away from its center. In the mouse retina, most of the cells in GCL are retinal ganglion 
cells concentrated in the center. Other cells in GCL are small glial cells and displaced 
amacrine cells. The displaced amacrine cells are concentrated in the periphery of the 
mouse retina rather than the center (Drager and Olsen, 1981). No effort was made to 
distinguish the retinal ganglion cells from other cells in the GCL. However, the 
purpose of taking the data from the center of the retina was to minimize the likelihood 
of counting the displaced amacrine cells and also to maintain the consistency of 
comparison throughout the subjects. 
 
5.3.6. Statistical analysis 
For the MB dose-response study, a between-groups one way ANOVA test with 
multiple comparisons and Bonferroni correction was used to evaluate GCL thickness 
in all groups, namely DMSO, rotenone alone, and rotenone plus three doses of MB. 
The “n” equals number of eyes.  
To test the significance of within-subject differences in GCL thickness and cell 
counts between the experimental eye (treated with rotenone or rotenone plus MB 0.07 
mg/kg) and the vehicle DMSO-treated control eye, paired t-tests were used with paired 
samples from both eyes of each subject. The “n” equals number of mice with pairs of 
treated and control eyes. 
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Repeated measures ANOVA were used to analyze cytochrome oxidase activity 
in the two groups. The “n” equals number of pairs of eyes. Mann-Whitney U-tests 
were used to test the percent differences from control in cytochrome oxidase activity 
of rotenone and MB/rotenone groups in IPL and optic nerve. All tests used a two-
tailed p < 0.05 as criterion for significant differences. 
 
5.4 RESULTS 
Microscopic examination of the retina stained with complex I or cresyl violet 
indicated that MB treatment reduced the thinning and cell death in GCL caused by 
rotenone. Figure 5.1 provides examples of cresyl violet-stained sections, showing that 
eyes treated with MB plus rotenone did not have the same degree of thinning in the 
GCL seen in the eyes treated with rotenone alone. 
 
 
Figure 5.1 Cross section of the retina with cresyl violet staining in DMSO (vehicle), 
rotenone (0.2 mg/kg), and MB (0.07 mg/kg) plus rotenone (0.2 mg/kg) 
treated eyes at 24 h post-injection time. The thickness of the ganglion cell 





Figure 5.2 shows that rotenone-induced neurodegeneration was reduced in a 
dose-dependent manner by addition of MB as indicated by the GCL thickness. There 
was a highly significant group difference due to MB treatment (F (4, 66) = 11.29, p = 
6.05x10-7). Individual group contrasts showed that the rotenone alone group had 
significant GCL reductions as compared to rotenone with the two higher MB doses (p 
= 0.004 and p = 0.00008, respectively). The lowest MB dose was ineffective because 
this group was not significantly different from the rotenone alone group (p = 1), and it 
still showed a significant GCL reduction as compared to the DMSO controls (p = 
0.014). The GCL measures of GCL thickness of rotenone with the two higher MB 
doses, however, were not different from those in DMSO control eyes (p = 1). The 
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observations in each MB dose indicated that the higher doses of MB completely 
prevented the GCL reduction caused by rotenone. 
 
Figure 5.2 Thickness (mean ± standard error bars) in the ganglion cell layer (GCL) 
of DMSO, rotenone (0.2 mg/kg) alone, and rotenone with three MB 
doses at 24 h post-injection time. * p < 0.05 compared to DMSO or 
MB/rotenone with MB at 0.007 mg/kg or 0.07 mg/kg. Sections stained 
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In addition to complex I staining, the neuroprotective action of the most 
effective MB dose was quantified using morphometric analysis of GCL thickness and 
stereological cell counts using routine cresyl violet staining. Figure 5.3A shows that 
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the thickness of the retinal GCL of the rotenone treated eyes was significantly reduced 
(paired t-test, n = 15, p = 0.01) compared to that of the DMSO control eyes. In 
contrast, in the eyes treated with rotenone plus MB 0.07 mg/kg there were no 
significant differences in GCL thickness as compared to the control eyes (paired t-test, 
n = 12, p = 0.21).  
The number of cells in the GCL was also reduced by 23% in the rotenone 
treated eyes (paired t-test, n = 6, p = 0.03, Figure 5.3B). Cell numbers in the GCL 
were not different between the MB/rotenone and the DMSO treated eyes (paired t-test, 
n = 12, p = 0.85).  
 
 
Figure 5.3 Thickness (A) and cell number (B) (mean ± standard error bars) in the 
ganglion cell layer (GCL) of DMSO (control), rotenone (0.2 mg/kg), and 
rotenone with MB (0.07 mg/kg) treated eyes at 24 h post-injection time. 
* p < 0.05 as compared to DMSO or MB/Rotenone groups. Sections 


























































Quantitative cytochrome oxidase histochemistry data in the IPL and the optic 
nerve showed that there was not a significant difference (rotenone or MB/rotenone) by 
group interaction in cellular oxygen consumption, but significantly higher cytochrome 
oxidase activity was detected in both the rotenone and MB/rotenone treated eyes as 
compared to their control eyes (repeated measures ANOVA, n = 18, p = 0.036 in the 
IPL; n = 18, p = 0.01 in the optic nerve). For the rotenone-treated eyes, cytochrome 
oxidase activity in the IPL showed an 18% increase, while the optic nerve showed a 
51% increase. In the MB/rotenone treated eyes, the IPL showed a 22% increase and 
the optic nerve showed a 37% increase. Mann-Whitney U-tests showed that these 
percent increases in cytochrome oxidase activity in the experimental eyes were similar 
in rotenone and MB/rotenone groups in both the IPL (n = 25, p = 0.8) and optic nerve 
(n = 25, p = 0.7), indicating that both treatments produced similar increases in 
cytochrome oxidase activity. 
 
5.5 DISCUSSION 
The neurodegeneration caused by rotenone in the GCL has been shown 
previously in our model of optic neuropathy (Zhang et al., 2002), and it was confirmed 
in the present study by using two different stains (complex I and Nissl stains), and 
both layer thickness and stereological cell counts as measures. All eyes were 
microinjected with the same drug volume and thus the results produced by the 
different drug treatments are unlikely to be due to differences in compression of the 
GCL from intraocular injection. Thus, it is unlikely that the effects of rotenone on 
GCL are nonspecific or are due to a particular staining or measurement artifact. 
 114 
Most importantly, the present study is the first to demonstrate that MB is 
effective in preventing GCL neurodegeneration (cell loss and layer thinning) 
following rotenone administration. The dose-response data indicated the potential of 
the higher MB dose to prevent ganglion cell degeneration, which was verified with 
cell counts using unbiased stereological methods. The highest MB dose we used (0.07 
mg/kg) was 1,000 times lower than the LD50 of MB for mice (77 mg/kg i.v.), 
suggesting that we worked with non-toxic MB doses. 
MB is an FDA-approved drug that has been used effectively as an antidote for 
certain metabolic poisons without significant side effects at doses of 1-2 mg/kg 
(Clifton and Leikin, 2003). MB has also been used as a neuroprotective agent in drug-
induced encephalopathy, dementia and manic-depressive psychosis (Naylor et al., 
1986; Kupfer et al., 1996; Wainwright and Crossley, 2002). Behaviorally, studies by 
Martinez et al. (1978) showed that MB (1 mg/kg, i.p.) given immediately after 
avoidance conditioning enhanced memory retention 24 h later. We have found that the 
same dose of MB reverses spatial memory deficits produced by sodium azide, an 
inhibitor of mitochondrial complex IV (Callaway et al., 2002). There is also enhanced 
memory retention in a food-search task in MB-treated rats relative to untreated 
controls 24 h after MB administration (Callaway et al., 2004).  
MB’s protective metabolic function has been documented to act through two 
main pharmacological mechanisms. One mechanism involves improving oxygen 
consumption and the other is related to its powerful antioxidant effects. MB acts as a 
redox agent that increases mitochondrial respiration by shuttling electrons to oxygen 
in the electron transport chain, resulting in elevated cellular oxygen consumption 
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(Callaway et al., 2004; Lindahl and Oberg, 1961; Visarius et al., 1997). MB has also 
been found to increase oxygen consumption on gill filaments pretreated with rotenone 
(Lindahl and Oberg, 1961). 
One major antioxidant action of MB is that it inhibits superoxide, the most 
abundant oxygen radical generated in vivo, by accepting electrons from tissue oxidases 
(Kelner et al., 1988; Salaris et al., 1991). Another antioxidant action of MB is due to 
its inhibition of nitric oxide synthesis (Mayer et al., 1993). Nitric oxide can form the 
damaging peroxynitrite after reacting with superoxide. Therefore, MB administration 
could be very effective in preventing mitochondrial oxidative damage leading to 
neurodegeneration (Gonzalez-Lima et al., 1998). 
In the current study and in our previous study (Zhang et al., 2002), rotenone 
stimulated cytochrome oxidase activity in the regions where the neuropil of the retinal 
ganglion cells reside (IPL and optic nerve), and rotenone induced neuronal death in 
the GCL after 24 h of administration (Zhang et al., 2002). The observed increase in 
cytochrome oxidase activity may be explained by a mechanism of excitotoxicity 
induced by rotenone in the retina. Excitotoxicity occurs when neurons are placed 
under adverse metabolic conditions such as exposure to certain toxins and increased 
levels of glutamate and oxidative stress (Coyle and Puttfarcken, 1993; Choi, 1988; 
Beal, 1998; Lafon-Cazal et al., 1993; Gunasekar et al., 1995; Lafon-Cazal et al., 
1993). 
An antioxidant interpretation of MB therapeutic action is consistent with other 
studies of toxin-induced inhibition of complex I. Inhibition of complex I by MPP+ or 
rotenone produces neurodegeneration in the striatum (Sherer et al., 2003). 
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Interestingly, complex I inhibition caused by MPP+ is blocked by antioxidants such as 
glutathione, catalase and ascorbate, implicating an antioxidant therapeutic mechanism 
(Cleeter et al., 1992). Further studies are needed to investigate the mechanisms of the 
neuroprotective action of MB on rotenone-induced neurodegeneration. 
In summary, MB is remarkably effective in preventing ganglion cell 
neurodegeneration caused by rotenone. This protective effect may be mediated 
through the antioxidant action of MB to prevent mitochondrial oxidative damage and 
excitotoxic cell death. The present results suggest that MB should be further 
investigated as a potential therapeutic agent to prevent neurodegeneration caused by 
mitochondrial dysfunction in diseases such as Leber’s optic neuropathy, Parkinson’s 
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Chapter 6: General Discussion and Future Directions 
6.1 GENERAL DISCUSSION  
Increasing evidence has suggested that the mitochondrion is a critical player in 
the life and death of neurons. Neurodegenerative diseases have been closely linked to 
the dysfunction of mitochondrial respiratory chain components, among which 
mitochondrial complex I (NADH dehydrogenase) is ranked first in many respects. It is 
the first enzyme of the respiratory chain, catalyzing the electron transfer from NADH 
to coenzyme Q and generating ubiquinol. It is the most complicated of the respiratory 
complexes, both in terms of protein structure and of genetics. It is the largest 
mitochondrial complex, consisting of 43 distinct protein subunits. It has the most 
(seven) mtDNA encoded subunits, while complex III, IV, and ATP synthase only have 
1, 3, and 2 respectively (Genova et al., 2004). The daunting complexity of complex I 
suggests that complex I may be more susceptible to environmental or genetic insults 
than other mitochondrial complexes. This might explain the phenomenon that a wide 
variety of neurodegenerative diseases are associated with complex I dysfunction; these 
include Leber's hereditary optic neuropathy (LHON), Parkinson's disease, and 
dystonia (Schapira, 1998). Among them, LHON has been recognized as a model 
disease for mitochondrial neurodegenerative diseases (Brown et al., 1992). 
A mouse model of optic neuropathy caused by mitochondrial complex I 
dysfunction was successfully created, as a part of this dissertation study, to help fulfill 
the need to develop effective in vivo animal models for exploring the underlying 
mechanisms and treatments for neurodegenerative diseases (Zhang et al., 2002). A 
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single intravitreal administration of rotenone, a complex I inhibitor, in mice started 
reducing the retinal ganglion cell layer (GCL) between 0.5-1 h without significantly 
affecting the rest of the retina. The maximum reduction in GCL thickness apparent in 
complex I staining was around 40% at 24 h following injection. The reduction was 
observed with both complex I histochemistry and with cresyl violet staining. The 
thickness of the retinal nerve fiber layer (RNFL) was reduced by 89% and the number 
of GCL cells was reduced by 21% (cell profile counts, experiment in Chapter 3) and 
23% (unbiased stereological cell counts, experiment in Chapter 5) in rotenone-treated 
eyes. There was a relative reduction in the proportion of larger cells, while no overall 
cellular morphometric changes (soma area, perimeter, and diameter) were observed. 
Therefore, the reduction in GCL thickness 24 h after rotenone microinjection could be 
accounted for by cell loss and nerve fiber shrinkage, but not by overall soma size 
change. The preferential loss of the larger ganglion cells has been reported in 
Alzheimer’s disease (Sadun and Bassi, 1990). It has also been seen in glaucoma 
(Quigley et al., 1988) and optic neuropathy induced by intravitreal injection of NMDA 
(N-methyl-D-aspartate) (Dreyer et al., 1994), both of which may be associated with 
ischemia and excitotoxicity. Excitotoxicity is a process of cell death in the nervous 
system due to overactivation of the glutamate receptors. The degeneration in the nerve 
fiber layer and the retinal ganglion cell layer in our model is consistent with the 
degeneration of retinal ganglion cells in Leber’s hereditary optic neuropathy. This is 
the first animal model of optic neuropathy resulting from mitochondrial dysfunction, 
and it could be used as an efficient and convenient way to test new treatments for 
mitochondrial neurodegenerative diseases.  
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Our first therapeutic intervention in this optic neuropathy model was to test the 
hypothesis that methylene blue, as an antioxidant, may be protective against rotenone-
induced neurodegeneration. Methylene blue is a reduction–oxidation agent that can act 
as a powerful antioxidant, preventing formation of mitochondrial oxygen free radicals 
by acting as an electron sink. The neurodegeneration in the retinal ganglion cell layer 
observed 24 h after rotenone injection was completely prevented by the injection of 
methylene blue along with rotenone, as indicated by both the thickness and cell 
numbers of the retinal ganglion cell layer. The effect of rotenone and rotenone plus 
methylene blue was investigated using two types of histological stains, complex I and 
Nissl, and two measurements, morphometric layer thickness and non-biased 
stereological cell counts. The protective effect of methylene blue appeared to be 
related to its antioxidant action because cytochrome oxidase activity was similarly 
elevated in both rotenone and rotenone plus methylene blue groups. It was concluded 
that methylene blue may be a promising therapeutic agent in optic neuropathy and 
perhaps other neurodegenerative diseases caused by mitochondrial dysfunction.  
Rotenone and MB can act at two levels, within the cells and in the interaction 
between the cells. In the intracellular level, rotenone will decrease oxygen 
consumption by inhibiting the respiratory chain, resulting in increased free radicals 
mostly coming from superoxide generation. Administration of MB enhances oxygen 
consumption while at the same time act as an antioxidant, preventing oxidative 
damage and cell death.  
In addition, rotenone may produce excitotoxicity through neuronal circuit 
mechanism, in which MB may also be protective as a powerful antioxidant. Figure 6.1 
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shows a schematic diagram of the proposed circuit mechanism of action of rotenone 
and MB in the retina. Visual information flow in the retina is through the 
neurotransmitter glutamate from the bipolar cells to the ganglion cells. Amacrine cells 
modulate this bipolar-ganglion cell pathway in the IPL. Rotenone has been shown to 
decrease the release of GABA in the striatum by intrastriatal injection (Brouillet et al., 
1994). It is possible that the release of GABA also reduced in response to intravitreal 
rotenone injection, which results in relatively elevated excitatory input to the ganglion 
cell from the bipolar cell, leading to excitotoxic cell death of the ganglion cells. In 
addition, amacrine cells are particularly sensitive to excitotoxicity because they 
express receptors for glutamate released from bipolar cells (Duarte et al., 1998). Since 
the inhibitory neurotransmitter -aminobutyric acid (GABA) is the major transmitter 
released from amacrine cells, impairment of amacrine cells by excitotoxicity may 
reduce the inhibitory input from GABA on the ganglion cells. This will further 
decrease the release of GABA and form a feed-forward cycle to facilitate 
excitotoxicity. The resulting metabolic overactivation of ganglion cells, as indicated 
by cytochrome oxidase activity in the IPL and optic nerve, may lead to excitotoxic 
death of ganglion cells through apoptosis (Chen et al., 2001; Choi, 1995; Mattson, 
2003). Excitotoxicity, triggered by excessive activation of glutamate receptors, has 
been postulated as a mechanism of neuronal death in a number of neurodegenerative 
disorders, such as Alzheimer’s, Parkinson’s, and Huntington's diseases (Choi, 1988; 
Coyle and Puttfarcken, 1993), as well as some eye diseases such as glaucoma and 




Figure 6.1 Proposed mechanism of the retinal ganglion cell death caused by 
rotenone and the protection by MB. Bipolar cells release glutamate to the 
amacrine and ganglion cells. Rotenone administration impairs amacrine 
cells which secrete the inhibitory neurotransmitter GABA. Without the 
modulation of GABA, the ganglion cells show glutamate-induced over-
activity as reflected by increased cytochrome oxidase activity. The 
antioxidant action of MB may prevent the oxidative damage that leads to 
excitotoxic cell death. IPL: inner plexiform layer.  : Excitatory 












1. Bipolar cell releases 
excitatory glutamate in IPL 
2. Amacrine cell release of 
inhibitory GABA is 
decreased by rotenone 
3. Increased cytochrome 
oxidase activity in the IPL 
4. Ganglion cell becomes 
overexcited and suffers 
oxidative stress 
5. Increased cytochrome 
oxidase activity in the optic 
nerve. Excitotoxic ganglion 
cell death occurs in 24 h if 
there is no antioxidant 
protection by MB 




In our study, MB may have acted as an antioxidant to prevent oxidative 
damage because rotenone and MB/rotenone treated eyes showed similar enhancement 
of cytochrome oxidase activity. A similar level of cytochrome oxidase activity implies 
a similar level of mitochondrial respiration and oxidative stress (Gonzalez-Lima et al., 
1998). MB effectively inhibits the production of superoxide, nitric oxide and hydroxyl 
radical (Kelner et al., 1988; Mayer et al., 1993). Complex I is particularly susceptible 
to inhibition by these free radicals (Zhang et al., 1990), which could aggravate the 
inhibition caused by rotenone. This suggests that in this rotenone-induced optic 
neuropathy, the neuroprotective action of MB may involve its antioxidant action to 
prevent oxidative damage and excitotoxic cell death. 
 
6.2 FUTURE DIRECTIONS: MORE THERAPEUTIC INTERVENTIONS  
6.2.1 Pharmacological approach: Anti-glutamatergic agent memantine 
Excitotoxicity is implicated in the pathophysiology of a wide variety of 
neurodegenerative diseases (Lipton and Rosenberg, 1994). It is induced at least in part 
by excessive activation of glutamate receptors (presumably the NMDA subtype) 
(Waxman and Lynch, 2005). When stimulated, the channel in the receptor opens and a 
large amount of Ca2+ flows into the neurons resulting in Ca2+ overload in the 
mitochondria. This, in turn, triggers a cascade of processes that can lead to apoptosis, 
a type of programmed cell death. High concentration of intracellular Ca2+ may activate 
calcium-dependent proteases and phospholipases that can destroy protein and lipid 
components of the cell, and may produce reactive oxygen species that are toxic to the 
cell. For example, Ca2+-dependent activation of nitric oxide synthase increases nitric 
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oxide production and the formation of toxic peroxynitrite; activation of certain protein 
kinases and transcription factors can further cause neuronal injury in the nucleus and 
eventually, cell death (Bonfoco et al., 1995; Budd et al., 2000; Dawson et al., 1993). 
A large amount of work has indicated the therapeutic effects of anti-excitatory 
agents, which block the activation of the glutamate receptors, on neurodegenerative 
diseases (Le and Lipton, 2001; Hynd et al., 2004; Palmer, 2001). However, the side 
effects of traditional anti-excitatory drugs are usually severe, ranging from drowsiness 
to coma (Hickenbottom and Grotta, 1998; Le and Lipton, 2001). Glutamate is the most 
common excitatory neurotransmitter that is widely distributed in the nervous system. 
It is essential for normal neuronal activities, though it is also detrimental when it is 
present in excessive amounts. Traditional anti-glutamatergic drugs are competitive 
antagonists, competing one for one with the agonist of the receptor (glutamate or 
glycine). They actually block normal, lower activation of the receptors before they can 
block pathological state with high levels of the agonists. Therefore, ideal anti-
excitotoxicity drugs should block only excessive activation of the glutamate receptors 
while sparing the normal neuronal transmission of the receptors. 
Memantine (1-amino-3,5-dimethyladamantane) is a drug that has such 
features. It is a derivative of amantadine, which is used in treating influenza and 
sometimes, Parkinson’s disease. It is a non-competitive open-channel (acts only when 
channel is open) NMDA receptor antagonist. Lipton (2003) reported that the degree of 
its blocking increases while the concentration of NMDA increases to pathological 
levels, which is the typical feature of a non-competitive antagonist. The binding site of 
memantine to the receptor is near the Mg2+ site, which, taken together with its non-
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competitive antagonist behavior, suggests that it only blocks NMDA receptor activity 
when the channel is open long enough for it to enter the channel, and the agonist is 
present in excessive amounts; both occur at pathological levels. This is supported by 
its clinical safety profile (Lipton, 1993). Memantine has been shown to reduce 
neuronal cell death and to be protective for neurons, including retinal ganglion cells in 
many recent in vitro and in vivo studies (Osborne, 1999; Schuettauf et al., 2002; 
Tremblay et al., 2000; Lipton, 2003; Hare et al., 2001). For example, Hare et al. 
(2001) reported that memantine-treated  glaucoma eyes suffered significantly less 
reduction of visually-evoked cortical potential (VECP) amplitude (at a dose of 4 
mg/kg/day, orally, for 15 months in monkeys) and significant reduction in glaucoma-
induced loss of retinal ganglion cells in rats (administered at 10 mg/kg/day, 
subcutaneous osmotic pump, for 3 weeks) when compared to control eyes. 
 
 








Because excitotoxicity is implicated in our animal model of neurodegeneration 
in the retina (see Chapter 5), anti-glutamatergic agents should also be of benefit to the 
treatment of neurodegeneration induced by rotenone in the GCL. We hypothesize that 
administration of memantine alone or in combination with methylene blue in the 
rotenone treated eye may prevent rotenone-generated retinal ganglion cell death. 
 
6.2.2 Non-pharmacological approach: Near infrared light with light-emitting 
diode  
Near infrared light (NIR) (wavelength range 630-900 nm) has been shown to 
promote wound healing in human and animal studies (Sommer et al., 2001; Yu et al., 
1997; Conlan et al., 1996). Low intensity is the key to this therapy because the 
photochemical conversion prevails over the heat-generation of the energy absorbed by 
a photoacceptor. Light-emitting diodes (LED) and lasers are two types of devices 
producing near infrared light that have been used in therapeutic wound healing studies. 
However, the LED has more beneficial features compared to the laser. Unlike the 
laser, the LED generates light with longer wavelengths that can penetrate deeper into 
tissue; the LED does not generate significant heat, and therefore does not cause 
thermal injuries; also, the LED is more compact and more affordable. For these 
reasons, the LED has achieved FDA non-significant risk (NSR) status as a therapeutic 
device (Eells et al., 2004).  
The mechanisms of the therapeutic action of NIR has been postulated to be 
associated with initial stimulation of cytochrome c oxidase activity (complex IV of 
mitochondrial respiratory chain) (Wong-Riley et al., 2004; Wong-Riley et al., 2001). 
The stimulation of cytochrome c oxidase triggers the activation of a signaling cascade 
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which promotes cellular proliferation and cytoprotection, including the activation of 
genes, transcription factors, elevated protein, growth factors and ATP synthesis 
(Wong-Riley et al., 2001; Karu, 1999; Eells et al., 2004; Mochizuki-Oda et al., 2002). 
Eells et al. (2004) reported that three brief (2 min 24 s) 670 nm LED treatments (4 
J/cm2) significantly reduced the retinal and optic nerve toxicities induced by methanol-
derived formate using their rat model of methanol intoxication. We propose that the 
LED treatment may ameliorate compensatory effects to complex I dysfunction by 
promoting complex IV activity and the cascade of events that may protect against 
neurodegeneration induced by rotenone toxicity. Our optic neuropathy model using 
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APPENDIX: Protocol of mitochondrial complex I histochemistry 
Make (or check) the solutions the day before staining: 
• 0.2 M phosphate buffer (PB), 3 L  
Add 3 L of ddH2O to a 4 L flask, 
Add 56.8 g of anhydrous dibasic-sodium phosphate (fw = 141.96), 
Add 27.6 g of monobasic-sodium phosphate (fw = 137.99), 
Stir until dissolved and filter if necessary, 
Adjust pH to 7.6, 
Refrigerate 
• 0.1 M phosphate buffer, 1.5 L 
Add 0.75 L 0.2 M PB to a 1.5 L flask, 
Add 0.75 L ddH2O, 
Stir and refrigerate 
• 10%w/v sucrose PB solution, 4 L 
Add 2 L of 0.2 M PB to a 6 L flask, 
Add 400 g of sucrose (fw = 342.31), 
Add 2 L ddH2O, 
Stir until dissolved, and then keep refrigerated, 
• 0.5% glutaraldehyde in 10% sucrose PB (The glutaraldehyde stock is 25%. 
Keep glutaraldehyde solution in the refrigerator until needed. Mix new solution 











11 – 50 slides 700 = 14 686 
10 slides 250 = 5 245 
< 8 slides 100 = 2 98 
• Ethanols (30%, 50%, 70%, 90%, 95%, 100%) and formalin (10%); Alcohols 
must made 24 h before use. 
 
Procedure of the day of staining: 
1. Prepare NBT solution (incubation solution): 
Set incubator temperature to 37°C and place glassware inside, 
Heat 0.1 M PB in the microwave to approximately 36°C (700 ml/ 1.5 min), 















70 ml/ 8 
slices 
PB(0.1M)  700 ml 250 ml 70 ml 
NBT 1.33 933.33 mg 332.5 mg 93.33 mg 
Sodium azide 0.065 45.5 mg 16.25 mg 4.55 mg 
NADH (N8129, 
sigma, FW 709.4) 
1 (=1.4mM) 700 mg 250 mg 70 mg 
Cover to shield from light and stir slowly (at about 270 RPM) until reaching 36°C. 
Pour into glassware in oven (Make sure everything is dissolved!) 
after filter the solution. 
 
2. Prepare fresh frozen tissue sections and place slides in racks. 
3. Remove 0.5% glutaraldehyde in 10% sucrose PB from refrigerator, and lower 
slide racks in very slowly and gently, 5 min. 
4. 10% sucrose PB, 3 changes, 5 min each: pour all just before step 3 ends so that 
each is subsequently warmer. 
5. 0.1 M PB rinse, 5 min, at room temperature. 
6. Incubate in NBT solution: Incubate with NBT solution at 37 °C in a dark oven, 
25 min (30-60 min). 
7. 0.1 M PB rinse, 5 min, at room temperature. 
8. Fix tissue: Transfer slide rack to 10% formalin, 30 min. 
9. Dehydrate: Dehydration bath of 30, 50, 70, 90, 95 (2 changes), 100% (2 
changes) ethanol, 5 min each. 
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10. Clear and coverslip: Xylene (3 changes), 5 min each. Coverslip slides with 
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